🏷

Classifications

Harrison's Chapter

👪

Inheritance

1

X-linked Recessive

The PLP1 gene is located on chromosome Xq22.2. Most affected individuals are males. Carrier females may show mild neurological signs.

Expressivity: VARIABLE

Show evidence (1 reference)

PMID:20301361 SUPPORT Human Clinical

"Heterozygous females may manifest mild-to-moderate features of the disease"

GeneReviews confirms X-linked inheritance with variable carrier manifestation.

◆

Subtypes

5

Classic Pelizaeus-Merzbacher Disease MONDO:0017222

Most common form, onset in first months of life with nystagmus and head titubation, followed by progressive spasticity, ataxia, and cognitive impairment.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"Classic PMD presents before the first year of age, with nystagmus, slowly acquired or unachieved motor milestones, and significant axial hypotonia"

Describes the clinical presentation and onset timing of classic PMD.

Connatal Pelizaeus-Merzbacher Disease MONDO:0017221

Severe form with neonatal onset, characterized by nystagmus, stridor, feeding difficulties, profound hypotonia progressing to spasticity, and severe developmental delay. Often fatal in childhood.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"Connatal PMD presents earliest, in the neonatal period, and is the most aggressive of PMD phenotypes. Babies with connatal PMD manifest extrapyramidal signs, laryngeal stridor, feeding difficulties and optic atrophy"

Describes the severe neonatal presentation of connatal PMD.

Transitional Pelizaeus-Merzbacher Disease MONDO:0017223

Intermediate severity between classic and connatal forms. Includes spastic paraplegia type 2 (SPG2), which is of later onset with predominant lower extremity spasticity.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"Transitional PMD combines clinical features of both the classic and connatal forms, and includes two principal phenotypes, spastic paraplegia and PLP1 null disease"

Describes transitional PMD and its relationship to SPG2.

PLP1 Null Syndrome

Caused by PLP1 null mutations. Milder CNS phenotype with peripheral neuropathy, as DM20 isoform partially compensates for PLP1 loss.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"The PLP1 null phenotype represents another syndrome later described by Garbern and colleagues, and is characterized by complicated spastic paraplegia, with mild to moderate demyelinating peripheral neuropathy and axonal injury"

Describes the PLP1 null phenotype with its characteristic peripheral neuropathy.

Female Carrier Pelizaeus-Merzbacher Disease MONDO:0017224

Symptomatic presentation in heterozygous females carrying pathogenic PLP1 variants. Manifestations are often milder or later-onset than in affected males but may include progressive spasticity and cognitive decline.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"When symptomatic, females tend to manifest a milder, later-onset phenotype than their related males, more commonly characterized by late onset progressive spasticity and cognitive decline"

Describes the symptomatic female-carrier phenotype and its typical relative severity.

⚙

Pathophysiology

11

PLP1 Missense Mutation Causing Protein Misfolding

Missense mutations in PLP1 cause the mutant proteolipid protein to misfold in the endoplasmic reticulum of oligodendrocytes. Misfolded PLP1 accumulates and cannot be properly incorporated into myelin membranes.

oligodendrocyte CL:0000128

PLP1 hgnc:9086

protein folding GO:0006457

structural constituent of myelin sheath GO:0019911

central nervous system white matter UBERON:0003544

Downstream

Unfolded Protein Response Activation in Oligodendrocytes ER-retained misfolded PLP1 activates oligodendrocyte ER stress and the unfolded protein response.

Microglial Activation in Diseased White Matter PMD tissue and models with PLP1 missense mutations can show microglial activation during disease progression.

Show evidence (1 reference)

PMID:15627202 SUPPORT Human Clinical

"Distinct types of mutations, including point mutations and genomic duplications and deletions, have been identified as causes of PMD/SPG2 that act through different molecular mechanisms"

Reviews distinct molecular mechanisms for different PLP1 mutation types including misfolding pathways.

Unfolded Protein Response Activation in Oligodendrocytes

Accumulation of misfolded PLP1 in the endoplasmic reticulum activates the unfolded protein response (UPR) and ER stress pathways in oligodendrocytes.

oligodendrocyte CL:0000128

response to endoplasmic reticulum stress GO:0034976

central nervous system white matter UBERON:0003544

Downstream

Oligodendrocyte Apoptosis Sustained UPR and ER stress drive oligodendrocyte death.

Show evidence (2 references)

PMID:17115121 SUPPORT Human Clinical

"the wide range of mutations that can occur but also for the effects of PLP1 mutations on both cell autonomous and non-cell autonomous processes in myelinating cells"

Describes how PLP1 mutations affect cell-autonomous processes including ER stress in oligodendrocytes.

PMID:31585094 SUPPORT In Vitro

"Previous work showed involvement of unfolded protein response (UPR) and endoplasmic reticulum (ER) stress pathways"

Directly confirms UPR and ER stress pathway involvement in PLP1-mutant oligodendrocytes.

Oligodendrocyte Apoptosis

Sustained ER stress from misfolded PLP1 triggers apoptosis of oligodendrocytes, leading to loss of myelin-forming cells in the CNS.

oligodendrocyte CL:0000128

apoptotic process GO:0006915

central nervous system white matter UBERON:0003544

Downstream

Defective CNS Myelination Loss of oligodendrocytes removes the cells needed to form compact CNS myelin.

Show evidence (2 references)

PMID:29478609 SUPPORT Human Clinical

"Accumulation in the ER leads to activation of the unfolded protein response (UPR) and consequent oligodendrocytic death"

Directly describes UPR-triggered oligodendrocyte death from ER-retained misfolded PLP1.

PMID:31585094 SUPPORT Model Organism

"reduced oligodendrocyte apoptosis and enabled myelin formation"

Iron chelation in jimpy mice reduced oligodendrocyte apoptosis, confirming apoptosis as a key cell death mechanism.

PLP1 Gene Duplication Causing Overexpression

PLP1 duplications, the most common cause of PMD (50-75% of cases), lead to overexpression of PLP1 protein.

oligodendrocyte CL:0000128

PLP1 hgnc:9086

structural constituent of myelin sheath GO:0019911

Downstream

Abnormal Cholesterol and Lipid Trafficking Excess PLP from duplication sequesters cholesterol in lysosomal compartments and disrupts lipid raft and sphingolipid trafficking.

Oligodendrocyte Maturation Arrest and Process Retraction PLP1 overexpression can arrest oligodendrocyte maturation and reduce oligodendroglial process extension before normal myelin formation.

Microglial Activation in Diseased White Matter PMD tissue and models with PLP1 duplications can show microglial activation during disease progression.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"PLP gene duplications are the most common cause of Pelizaeus-Merzbacher disease"

Confirms PLP1 duplications as the most common mutation type.

Abnormal Cholesterol and Lipid Trafficking

Excess PLP1 from gene duplication causes sequestration of cholesterol in lysosomal compartments, resulting in abnormal trafficking of lipid rafts and sphingolipids, leading to oligodendrocyte injury and death.

oligodendrocyte CL:0000128

lipid transport GO:0006869

central nervous system white matter UBERON:0003544

Downstream

Defective CNS Myelination Lipid-trafficking disruption injures oligodendrocytes and compromises myelin assembly.

Show evidence (1 reference)

PMID:29478609 SUPPORT Model Organism

"Increased levels of PLP may lead to sequestration of cholesterol in the lysosomal compartments, resulting in abnormal cellular trafficking of lipid rafts and sphingolipids that are normally sorted out of the Golgi compartments, and this in turn may result in oligodendrocyte injury and early..."

Describes the mechanism by which PLP1 overexpression leads to oligodendrocyte dysfunction through lipid trafficking defects.

Oligodendrocyte Maturation Arrest and Process Retraction

PLP1 overexpression in oligodendrocytes can prevent normal maturation and limit oligodendroglial process extension. This reduces the ability of oligodendrocytes to ensheath axons and contributes to CNS hypomyelination.

oligodendrocyte CL:0000128

oligodendrocyte differentiation GO:0048709

central nervous system white matter UBERON:0003544

Downstream

Defective CNS Myelination Maturation-arrested oligodendrocytes cannot generate the normal myelin sheath needed for CNS white matter development.

Show evidence (1 reference)

PMID:29478609 SUPPORT Model Organism

"Some studies show evidence of oligodendrocyte maturation arrest and eventual cell death, associated with swelling of the Golgi apparatus"

PLP1-overexpressing mouse models show oligodendrocyte maturation arrest, supporting this duplication-specific pathophysiology branch.

PLP1 Null Mutation Causing Axon-Glial Support Failure

PLP1 deletions and null mutations can leave myelin structure relatively preserved compared with toxic gain-of-function variants, but loss of PLP disrupts axon-glial support and predisposes to axonal injury and peripheral neuropathy.

oligodendrocyte CL:0000128

PLP1 hgnc:9086

CNS myelination GO:0022010

structural constituent of myelin sheath GO:0019911

central nervous system white matter UBERON:0003544

Downstream

Peripheral Nerve Demyelination and Axonal Injury PLP1 null states are especially associated with peripheral demyelinating neuropathy and axonal injury.

Defective CNS Myelination PLP1 null states remain in the PLP1-related hypomyelinating spectrum, but typically produce milder CNS involvement than toxic missense or dosage gain mechanisms.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"both PLP-deficient mice and patients with PLP null mutations show evidence of axonal injury"

Supports loss of PLP-dependent axon-glial support as a null-mutation mechanism distinct from toxic misfolding or overexpression.

Peripheral Nerve Demyelination and Axonal Injury

In PLP1 null syndrome, peripheral nerves can show demyelinating neuropathy with axonal injury, creating a mutation-class-specific path to the peripheral neuropathy phenotype.

Schwann cell CL:0002573

peripheral nervous system myelination GO:0022011

Downstream

Peripheral Neuropathy Peripheral demyelination and axonal injury produce the clinically observed demyelinating peripheral neuropathy in PLP1 null syndrome.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"The PLP1 null phenotype represents another syndrome later described by Garbern and colleagues, and is characterized by complicated spastic paraplegia, with mild to moderate demyelinating peripheral neuropathy and axonal injury"

Directly links the PLP1 null subtype to demyelinating peripheral neuropathy and axonal injury.

Defective CNS Myelination

Regardless of the specific PLP1 mutation type, the downstream consequence is a failure of normal CNS myelination. Oligodendrocytes either die before forming myelin or produce structurally abnormal myelin sheaths. MRI shows diffuse hypomyelination of the cerebral white matter.

oligodendrocyte CL:0000128

CNS myelination GO:0022010

cerebral white matter UBERON:0002437

Downstream

Leukodystrophy Diffuse CNS hypomyelination produces the defining leukodystrophy and MRI phenotype.

Delayed Motor Development Early CNS hypomyelination disrupts motor pathway maturation and causes delayed or unachieved motor milestones.

Nystagmus Hypomyelinating white matter disease is associated with early ocular motor dysfunction and pendular nystagmus.

Hypotonia Early CNS hypomyelination contributes to the initial axial hypotonia seen in classic and connatal PMD.

Head Titubation The same early neurologic dysfunction that produces nystagmus is associated with head tremor or titubation in classic PMD.

Progressive Spasticity Progressive involvement of long motor tracts and corticospinal pathways produces spasticity after the initial hypotonic phase.

Ataxia Cerebellar and central white matter involvement contributes to ataxia.

Intellectual Disability Diffuse developmental hypomyelination contributes to cognitive impairment.

Dysarthria Spastic, cerebellar, and corticobulbar pathway involvement contributes to dysarthria.

Dysphagia Severe neurologic involvement can impair swallowing and require feeding support.

Choreoathetosis Extrapyramidal pathway involvement contributes to choreoathetoid movements.

Dystonia Extrapyramidal involvement in PMD can manifest as dystonia.

Seizures Severe CNS involvement can predispose to seizures, particularly later in the course or in severe forms.

Optic Atrophy CNS white matter and visual pathway involvement can culminate in optic atrophy.

Laryngeal Stridor Brainstem and corticobulbar dysfunction in connatal PMD contributes to laryngeal stridor.

Show evidence (2 references)

PMID:27882623 SUPPORT Human Clinical

"all forms of the disease result in central hypomyelination, associated in most cases with early neurological dysfunction, progressive deterioration, and ultimately death"

Confirms that all forms of PMD share the feature of central hypomyelination.

PMID:29478609 SUPPORT Human Clinical

"There is a marked deficiency of myelin, particularly in deeper cerebral structures, but relative myelin preservation in areas surrounding blood vessels, providing the classic tigroid appearance of PMD histopathology"

Describes the characteristic histopathological pattern of myelin deficiency in PMD.

Microglial Activation in Diseased White Matter

Microglial activation has been reported in PMD patient biopsies and animal models with PLP1 missense mutations or duplications, indicating innate immune activation can accompany disease progression.

microglial cell CL:0000129

neuroinflammatory response GO:0150076

central nervous system white matter UBERON:0003544

Downstream

Defective CNS Myelination Neuroinflammatory activation is a superimposed disease-progression process associated with the dysmyelinating white matter state.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"microglial activation has been reported in biopsies of patients with both PLP1 missense mutations and duplications, as well as in animal models with similar mutations"

Review evidence supports microglial activation as a neuroinflammatory component in PMD tissues and matching animal models.

Iron-Dependent Oligodendrocyte Death (Ferroptosis)

PLP1-mutant oligodendrocytes exhibit hallmarks of ferroptosis including lipid peroxidation, abnormal iron metabolism, and hypersensitivity to free iron. Iron chelation with deferiprone rescues oligodendrocyte apoptosis and enables myelin formation in preclinical models, representing an additional death mechanism beyond ER stress-mediated apoptosis.

oligodendrocyte CL:0000128

ferroptosis GO:0097707

central nervous system white matter UBERON:0003544

Downstream

Defective CNS Myelination Iron-dependent oligodendrocyte death reduces oligodendrocyte survival and myelin formation.

Show evidence (2 references)

PMID:31585094 SUPPORT In Vitro

"Mutant oligodendrocytes demonstrated key hallmarks of ferroptosis including lipid peroxidation, abnormal iron metabolism, and hypersensitivity to free iron"

iPSC-derived PLP1-mutant oligodendrocytes show ferroptosis hallmarks including lipid peroxidation and abnormal iron metabolism.

PMID:31585094 SUPPORT Model Organism

"systemic treatment of Plp1 mutant Jimpy mice with deferiprone, a small molecule iron chelator, reduced oligodendrocyte apoptosis and enabled myelin formation"

Iron chelation rescues oligodendrocyte death and enables myelination in the jimpy mouse model.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

17

Digestive 1

Dysphagia Dysphagia HP:0002015

Severe bulbar involvement may require feeding support such as gastrostomy.

Show evidence (1 reference)

PMID:20301361 SUPPORT Human Clinical

"gastrostomy for individuals with severe dysphagia"

GeneReviews includes dysphagia severe enough to require gastrostomy among PLP1-related disorder manifestations managed clinically.

Eye 2

Nystagmus VERY_FREQUENT Nystagmus HP:0000639

Often the earliest sign, appearing in the first weeks to months of life. Typically pendular nystagmus.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"it is characterized by pendular nystagmus, head tremor, and systemic hypotonia"

Nystagmus is described as one of the cardinal features of prototypic PMD.

Optic Atrophy OCCASIONAL Optic atrophy HP:0000648

May develop later in disease course, particularly in connatal form.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"Optic atrophy and seizures may occur later in the course, although seizures are uncommon, and typically treatable"

Optic atrophy is described as a later-onset feature of classic PMD.

Musculoskeletal 3

Hypotonia VERY_FREQUENT Hypotonia HP:0001252

Early hypotonia that typically transitions to spasticity with age.

Show evidence (1 reference)

PMID:20301361 SUPPORT Human Clinical

"PMD typically manifests in infancy or early childhood with nystagmus, hypotonia, and cognitive impairment"

GeneReviews confirms hypotonia as a typical early manifestation of PMD.

Progressive Spasticity VERY_FREQUENT Progressive spasticity HP:0002191

Develops after initial hypotonic phase, often becoming the predominant motor finding.

Sequelae: Scoliosis

Show evidence (1 reference)

PMID:20301361 SUPPORT Human Clinical

"the findings progress to severe spasticity and ataxia"

GeneReviews confirms progressive spasticity as a major feature of PMD.

Scoliosis FREQUENT Scoliosis HP:0002650

Develops as a consequence of spasticity and immobility.

Show evidence (1 reference)

PMID:20301361 SUPPORT Human Clinical

"individuals with scoliosis benefit from proper wheelchair seating and physical therapy; surgery may be required for severe scoliosis"

GeneReviews describes scoliosis management as part of PMD care, confirming it as a recognized complication.

Nervous System 10

Ataxia FREQUENT Ataxia HP:0001251

Cerebellar ataxia contributing to motor impairment and gait difficulties.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"affected patients manifest some combination of mental retardation, choreoathetosis, dystonia, cerebellar ataxia and long tract signs"

Cerebellar ataxia is listed among the neurological manifestations of PMD.

Intellectual Disability FREQUENT Intellectual disability HP:0001249

Variable severity; ranges from mild to severe depending on PMD form.

Show evidence (1 reference)

PMID:20301361 SUPPORT Human Clinical

"PMD typically manifests in infancy or early childhood with nystagmus, hypotonia, and cognitive impairment"

Cognitive impairment is a core feature of PMD per GeneReviews.

Dysarthria FREQUENT Dysarthria HP:0001260

Speech difficulties due to spasticity and cerebellar involvement.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"spasticity of the lower extremities that can be isolated, or co-exist with varying degrees of cognitive impairment, nystagmus, ataxia, dysarthria and spastic urinary bladder"

Dysarthria is listed among the neurological features associated with PLP1-related disorders.

Head Titubation FREQUENT Head titubation HP:0002599

Involuntary rhythmic head movement, characteristic of classic PMD.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"it is characterized by pendular nystagmus, head tremor, and systemic hypotonia"

Head tremor (titubation) is described as a cardinal feature of prototypic PMD.

Leukodystrophy VERY_FREQUENT Leukodystrophy HP:0002415

MRI shows diffuse hypomyelination of cerebral white matter.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"MRI subsequently revealed overt hypomyelination, as reflected by the failure of PMD patients to develop the expected developmental increase in T1 and decrease in T2 signals characteristic of myelin maturation"

Describes the characteristic MRI finding of hypomyelination in PMD.

Delayed Motor Development VERY_FREQUENT Delayed gross motor development HP:0002194

Significant delays in achieving motor milestones; many patients never walk independently.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"Classic PMD presents before the first year of age, with nystagmus, slowly acquired or unachieved motor milestones, and significant axial hypotonia"

Delayed or unachieved motor milestones are a core feature of classic PMD.

Choreoathetosis FREQUENT Choreoathetosis HP:0001266

Involuntary movements including choreoathetosis and dystonia.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"affected patients manifest some combination of mental retardation, choreoathetosis, dystonia, cerebellar ataxia and long tract signs"

Choreoathetosis is listed among the neurological manifestations of PMD.

Dystonia Dystonia HP:0001332

Extrapyramidal motor involvement may include dystonia.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"affected patients manifest some combination of mental retardation, choreoathetosis, dystonia, cerebellar ataxia and long tract signs"

Dystonia is listed among neurological manifestations of PMD.

Seizures OCCASIONAL Seizure HP:0001250

Seizures may occur, particularly in connatal form. Typically responsive to antiepileptic agents.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"Optic atrophy and seizures may occur later in the course, although seizures are uncommon, and typically treatable"

Seizures occur but are uncommon and typically treatable in classic PMD.

Peripheral Neuropathy OCCASIONAL Demyelinating peripheral neuropathy HP:0007108

Primarily associated with PLP1 null mutations and deletions. Demyelinating type.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"The PLP1 null phenotype represents another syndrome later described by Garbern and colleagues, and is characterized by complicated spastic paraplegia, with mild to moderate demyelinating peripheral neuropathy and axonal injury"

Demyelinating peripheral neuropathy is characteristic of PLP1 null syndrome.

Respiratory 1

Laryngeal Stridor OCCASIONAL Stridor HP:0010307

Characteristic of connatal form. Due to laryngeal involvement.

Show evidence (1 reference)

PMID:29478609 SUPPORT Human Clinical

"Babies with connatal PMD manifest extrapyramidal signs, laryngeal stridor, feeding difficulties and optic atrophy"

Laryngeal stridor is a characteristic feature of connatal PMD.

🧬

Genetic Associations

1

PLP1 (Causative)

Gene: PLP1 hgnc:9086

Show evidence (3 references)

PMID:15627202 SUPPORT Human Clinical

"Both PMD and SPG2 are caused by mutations in the proteolipid protein 1 (PLP1) gene, which encodes a major component of CNS myelin proteins"

Confirms PLP1 as the causative gene for PMD.

PMID:17115121 SUPPORT Human Clinical

"Pelizaeus-Merzbacher disease (PMD) and the allelic spastic paraplegia type 2 (SPG2) arise from mutations in the X-linked gene encoding myelin proteolipid protein (PLP)"

Confirms the genetic basis of PMD in PLP1 mutations.

CGGV:assertion_c1a44c5f-744e-4d02-a08f-e7c687531b21-2018-03-07T110000.000Z SUPPORT Other

ClinGen classifies the PLP1-Pelizeaus-Merzbacher spectrum disorder gene-disease relationship as definitive with X-linked inheritance.

💊

Medical Actions

7

Supportive Care

Action: Supportive Care NCIT:C15747

No cure exists for PMD. Treatment is supportive and includes physical therapy, occupational therapy, and management of spasticity with medications such as baclofen. Seizure management with antiepileptic drugs when needed.

Show evidence (1 reference)

PMID:20301361 SUPPORT Human Clinical

"routine management of spasticity including physical therapy, exercise, medications (baclofen, diazepam, tizanidine), orthotics, and surgery for joint contractures"

GeneReviews describes the multidisciplinary supportive care approach for PMD management.

Physical Therapy

Action: Physical Therapy NCIT:C15302

Rehabilitation to maintain mobility, prevent contractures, and optimize functional abilities.

Show evidence (1 reference)

PMID:20301361 SUPPORT Human Clinical

"physical and occupational therapy for ataxia with adaptive devices as needed"

GeneReviews recommends physical and occupational therapy as part of PMD management.

Stem Cell Transplantation (Investigational)

Action: neural stem cell transplantation Ontology label: cellular therapy MAXO:0000016

Neural stem cell and glial progenitor cell transplantation are being investigated as potential therapies for PMD, aiming to provide donor-derived oligodendrocytes capable of myelinating host axons.

Mechanism Target:

MODULATES Defective CNS Myelination — Transplanted neural stem cells and glial progenitors can differentiate into donor-derived oligodendrocytes capable of myelinating host axons, directly targeting the defective CNS myelination that is the central phenotypic consequence of PLP1 pathology.

Show evidence (1 reference)

PMID:27882623 SUPPORT Human Clinical

"PMD and similar hypomyelinating disorders are attractive therapeutic targets for neural stem cell and glial progenitor cell transplantation, efforts at which are now underway in a number of research centers"

Reviews the rationale and ongoing efforts for stem cell-based therapy in PMD.

PLP1 Antisense Oligonucleotide Therapy (Investigational)

Action: antisense oligonucleotide therapy Ontology label: antisense oligonucleotide inhibitor therapy MAXO:0001593

Antisense oligonucleotides (ASOs) targeting PLP1 mRNA to suppress expression have shown dramatic preclinical efficacy in the jimpy mouse model, fully restoring oligodendrocyte numbers, myelination, motor function, and lifespan. This approach exploits the observation that PLP1-null individuals have milder disease than those with gain-of-function mutations.

Mechanism Target:

INHIBITS PLP1 Gene Duplication Causing Overexpression — PLP1-targeting ASOs suppress PLP1 mRNA levels, reducing the toxic overexpression of PLP1 protein caused by gene duplication and relieving the unfolded protein response-driven oligodendrocyte apoptosis.

INHIBITS PLP1 Missense Mutation Causing Protein Misfolding — ASO-mediated knockdown of PLP1 mRNA also reduces the load of misfolded PLP1 protein in oligodendrocytes bearing missense mutations, attenuating UPR activation and oligodendrocyte apoptosis.

Show evidence (1 reference)

PMID:32610343 SUPPORT Model Organism

"Administration of a single dose of Plp1-targeting antisense oligonucleotides in postnatal jimpy mice fully restored oligodendrocyte numbers, increased myelination, improved motor performance, normalized respiratory function and extended lifespan up to an eight-month end point"

Landmark Nature study demonstrating that ASO-mediated PLP1 suppression rescues the jimpy mouse model of severe PMD.

Deferiprone Iron Chelation (Investigational)

Action: Pharmacotherapy NCIT:C15986

Agent: deferiprone CHEBI:68554

Iron chelation with deferiprone is an investigational strategy targeting iron-dependent oligodendrocyte death. In Plp1 mutant Jimpy mice, systemic deferiprone reduced oligodendrocyte apoptosis and enabled myelin formation.

Mechanism Target:

INHIBITS Iron-Dependent Oligodendrocyte Death (Ferroptosis) — Deferiprone chelates iron and reduces the iron-dependent oligodendrocyte death branch of the PMD pathograph.

Show evidence (1 reference)

PMID:31585094 SUPPORT Model Organism

"systemic treatment of Plp1 mutant Jimpy mice with deferiprone, a small molecule iron chelator, reduced oligodendrocyte apoptosis and enabled myelin formation"

Preclinical mouse evidence supports deferiprone as an investigational iron-chelation approach for PMD ferroptosis.

Genetic Counseling

Action: Genetic Counseling NCIT:C15240

Counseling for X-linked inheritance, carrier testing, recurrence risk, and prenatal or preimplantation genetic testing once the familial PLP1 pathogenic variant is known.

Show evidence (1 reference)

PMID:20301361 SUPPORT Human Clinical

"Once the PLP1 pathogenic variant has been identified in an affected family member, heterozygote detection and prenatal and preimplantation genetic testing are possible"

GeneReviews supports genetic counseling and reproductive testing for families with PLP1-related disorders.

Speech Therapy

Action: speech therapy MAXO:0000930

Speech therapy is part of multidisciplinary supportive rehabilitation for PMD, particularly when communication or bulbar dysfunction contributes to disability.

Show evidence (1 reference)

DOI:10.18231/j.ijn.2024.037 SUPPORT Human Clinical

"Management involved a multidisciplinary approach, incorporating play therapy, speech therapy, physiotherapy for spasticity, and behavioral therapy"

Case-report evidence lists speech therapy as part of PMD multidisciplinary management.

🔬

Clinical Trials

2

NCT05659901 NOT_APPLICABLE RECRUITING

Rocket observational study characterizing longitudinal PLP1 protein, disease-related CSF and blood biomarkers, neuroimaging parameters, and clinical, participant, and caregiver-reported outcomes in participants with Pelizaeus-Merzbacher disease to support therapy development.

Show evidence (1 reference)

clinicaltrials:NCT05659901 SUPPORT Human Clinical

"The purpose of the study is to prospectively assess longitudinal changes in proteolipid protein 1 (PLP1) protein, disease-related biomarkers in cerebral spinal fluid (CSF) and blood, neuroimaging parameters relevant to Pelizaeus-Merzbacher disease (PMD) and longitudinal changes in performance on..."

Observational PMD natural-history and biomarker study identified by the Falcon research report.

NCT06150716 PHASE_I RECRUITING

Orbit study evaluating intrathecal ION356, a PLP1-targeting antisense oligonucleotide, in pediatric males with genetically confirmed PLP1 duplication PMD. Multiple ascending dose design with 48-week treatment and 109-week long-term extension.

Show evidence (1 reference)

clinicaltrials:NCT06150716 SUPPORT Human Clinical

"The primary purpose of this study is to evaluate the safety and tolerability of ION356"

Phase 1b trial of PLP1-lowering ASO therapy for PMD with PLP1 duplication.

{ }

Source YAML

click to show

name: Pelizaeus-Merzbacher Disease
creation_date: "2026-03-14T12:00:00Z"
updated_date: "2026-04-26T06:38:37Z"
category: Genetic
parents:
- Leukodystrophy
- X-linked Recessive Disorder
disease_term:
  preferred_term: Pelizaeus-Merzbacher disease
  term:
    id: MONDO:0010714
    label: Pelizaeus-Merzbacher spectrum disorder
description: >
  Pelizaeus-Merzbacher disease (PMD) is an X-linked recessive hypomyelinating
  leukodystrophy caused by mutations in the PLP1 gene encoding proteolipid protein 1,
  the major structural protein of central nervous system myelin. PLP1 mutations lead to
  defective myelination through various mechanisms including protein misfolding,
  endoplasmic reticulum stress, oligodendrocyte apoptosis, and gene dosage effects.
  Clinical features include nystagmus, hypotonia, spasticity, ataxia, intellectual
  disability, and progressive motor deterioration. PMD is classified into connatal
  (severe), classic, and transitional forms based on age of onset and severity.
prevalence:
- population: Global
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_1000000
  rate_low: 0.2
  rate_high: 0.5
  percentage: 1 in 200,000 to 500,000
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "their diagnosed prevalence ranges from 1:200,000–1:500,000 in the US, with international incidence ranging from 1:90,000–1:750,000 live births"
    explanation: Provides prevalence estimates for PMD from US and international data.
  notes: >
    PMD predominantly affects males due to X-linked recessive inheritance.
    Carrier females may occasionally show mild symptoms.
progression:
- phase: Onset
  age_range: Infancy
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Classic PMD presents before the first year of age, with nystagmus, slowly acquired or unachieved motor milestones, and significant axial hypotonia"
    explanation: Describes onset timing and initial features of classic PMD.
  notes: >
    Classic PMD presents in first months of life with nystagmus and hypotonia.
    Connatal form presents at birth with more severe symptoms including stridor.
- phase: Progression
  age_range: Childhood-Adulthood
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Appendicular spasticity and involuntary movements both follow this initial presentation"
    explanation: Describes the progressive nature of motor deterioration in classic PMD.
  notes: >
    Progressive spasticity, ataxia, and cognitive decline. Life span varies from
    adolescence to young adulthood in classic PMD; connatal form often fatal in childhood.
inheritance:
- name: X-linked Recessive
  description: >
    The PLP1 gene is located on chromosome Xq22.2. Most affected individuals are
    males. Carrier females may show mild neurological signs.
  expressivity: VARIABLE
  evidence:
  - reference: PMID:20301361
    reference_title: "PLP1-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Heterozygous females may manifest mild-to-moderate features of the disease"
    explanation: GeneReviews confirms X-linked inheritance with variable carrier manifestation.
has_subtypes:
- name: Classic Pelizaeus-Merzbacher Disease
  description: >
    Most common form, onset in first months of life with nystagmus and head titubation,
    followed by progressive spasticity, ataxia, and cognitive impairment.
  subtype_term:
    preferred_term: Pelizaeus-Merzbacher disease, classic form
    term:
      id: MONDO:0017222
      label: Pelizaeus-Merzbacher disease, classic form
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Classic PMD presents before the first year of age, with nystagmus, slowly acquired or unachieved motor milestones, and significant axial hypotonia"
    explanation: Describes the clinical presentation and onset timing of classic PMD.
- name: Connatal Pelizaeus-Merzbacher Disease
  description: >
    Severe form with neonatal onset, characterized by nystagmus, stridor, feeding
    difficulties, profound hypotonia progressing to spasticity, and severe
    developmental delay. Often fatal in childhood.
  subtype_term:
    preferred_term: Pelizaeus-Merzbacher disease, connatal form
    term:
      id: MONDO:0017221
      label: Pelizaeus-Merzbacher disease, connatal form
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Connatal PMD presents earliest, in the neonatal period, and is the most aggressive of PMD phenotypes. Babies with connatal PMD manifest extrapyramidal signs, laryngeal stridor, feeding difficulties and optic atrophy"
    explanation: Describes the severe neonatal presentation of connatal PMD.
- name: Transitional Pelizaeus-Merzbacher Disease
  description: >
    Intermediate severity between classic and connatal forms. Includes spastic
    paraplegia type 2 (SPG2), which is of later onset with predominant lower
    extremity spasticity.
  subtype_term:
    preferred_term: Pelizaeus-Merzbacher disease, transitional form
    term:
      id: MONDO:0017223
      label: Pelizaeus-Merzbacher disease, transitional form
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Transitional PMD combines clinical features of both the classic and connatal forms, and includes two principal phenotypes, spastic paraplegia and PLP1 null disease"
    explanation: Describes transitional PMD and its relationship to SPG2.
- name: PLP1 Null Syndrome
  description: >
    Caused by PLP1 null mutations. Milder CNS phenotype with peripheral neuropathy,
    as DM20 isoform partially compensates for PLP1 loss.
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The PLP1 null phenotype represents another syndrome later described by Garbern and colleagues, and is characterized by complicated spastic paraplegia, with mild to moderate demyelinating peripheral neuropathy and axonal injury"
    explanation: Describes the PLP1 null phenotype with its characteristic peripheral neuropathy.
- name: Female Carrier Pelizaeus-Merzbacher Disease
  description: >
    Symptomatic presentation in heterozygous females carrying pathogenic PLP1
    variants. Manifestations are often milder or later-onset than in affected
    males but may include progressive spasticity and cognitive decline.
  subtype_term:
    preferred_term: Pelizaeus-Merzbacher disease in female carriers
    term:
      id: MONDO:0017224
      label: Pelizaeus-Merzbacher disease in female carriers
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "When symptomatic, females tend to manifest a milder, later-onset phenotype than their related males, more commonly characterized by late onset progressive spasticity and cognitive decline"
    explanation: Describes the symptomatic female-carrier phenotype and its typical relative severity.
pathophysiology:
- name: PLP1 Missense Mutation Causing Protein Misfolding
  description: >
    Missense mutations in PLP1 cause the mutant proteolipid protein to misfold in the
    endoplasmic reticulum of oligodendrocytes. Misfolded PLP1 accumulates and cannot
    be properly incorporated into myelin membranes.
  genes:
  - preferred_term: PLP1
    term:
      id: hgnc:9086
      label: PLP1
  molecular_functions:
  - preferred_term: structural constituent of myelin sheath
    term:
      id: GO:0019911
      label: structural constituent of myelin sheath
  downstream:
  - target: Unfolded Protein Response Activation in Oligodendrocytes
    description: >
      ER-retained misfolded PLP1 activates oligodendrocyte ER stress and the
      unfolded protein response.
    causal_link_type: DIRECT
  - target: Microglial Activation in Diseased White Matter
    description: >
      PMD tissue and models with PLP1 missense mutations can show microglial
      activation during disease progression.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: protein folding
    term:
      id: GO:0006457
      label: protein folding
  locations:
  - preferred_term: central nervous system white matter
    term:
      id: UBERON:0003544
      label: brain white matter
  evidence:
  - reference: PMID:15627202
    reference_title: "PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Distinct types of mutations, including point mutations and genomic duplications and deletions, have been identified as causes of PMD/SPG2 that act through different molecular mechanisms"
    explanation: Reviews distinct molecular mechanisms for different PLP1 mutation types including misfolding pathways.
- name: Unfolded Protein Response Activation in Oligodendrocytes
  description: >
    Accumulation of misfolded PLP1 in the endoplasmic reticulum activates the
    unfolded protein response (UPR) and ER stress pathways in oligodendrocytes.
  downstream:
  - target: Oligodendrocyte Apoptosis
    description: >
      Sustained UPR and ER stress drive oligodendrocyte death.
    causal_link_type: DIRECT
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: response to endoplasmic reticulum stress
    term:
      id: GO:0034976
      label: response to endoplasmic reticulum stress
  locations:
  - preferred_term: central nervous system white matter
    term:
      id: UBERON:0003544
      label: brain white matter
  evidence:
  - reference: PMID:17115121
    reference_title: "Pelizaeus-Merzbacher disease: Genetic and cellular pathogenesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the wide range of mutations that can occur but also for the effects of PLP1 mutations on both cell autonomous and non-cell autonomous processes in myelinating cells"
    explanation: Describes how PLP1 mutations affect cell-autonomous processes including ER stress in oligodendrocytes.
  - reference: PMID:31585094
    reference_title: "Oligodendrocyte Death in Pelizaeus-Merzbacher Disease Is Rescued by Iron Chelation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Previous work showed involvement of unfolded protein response (UPR) and endoplasmic reticulum (ER) stress pathways"
    explanation: Directly confirms UPR and ER stress pathway involvement in PLP1-mutant oligodendrocytes.
- name: Oligodendrocyte Apoptosis
  description: >
    Sustained ER stress from misfolded PLP1 triggers apoptosis of oligodendrocytes,
    leading to loss of myelin-forming cells in the CNS.
  downstream:
  - target: Defective CNS Myelination
    description: >
      Loss of oligodendrocytes removes the cells needed to form compact CNS
      myelin.
    causal_link_type: DIRECT
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: apoptotic process
    term:
      id: GO:0006915
      label: apoptotic process
  locations:
  - preferred_term: central nervous system white matter
    term:
      id: UBERON:0003544
      label: brain white matter
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Accumulation in the ER leads to activation of the unfolded protein response (UPR) and consequent oligodendrocytic death"
    explanation: Directly describes UPR-triggered oligodendrocyte death from ER-retained misfolded PLP1.
  - reference: PMID:31585094
    reference_title: "Oligodendrocyte Death in Pelizaeus-Merzbacher Disease Is Rescued by Iron Chelation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "reduced oligodendrocyte apoptosis and enabled myelin formation"
    explanation: Iron chelation in jimpy mice reduced oligodendrocyte apoptosis, confirming apoptosis as a key cell death mechanism.
- name: PLP1 Gene Duplication Causing Overexpression
  description: >
    PLP1 duplications, the most common cause of PMD (50-75% of cases), lead to
    overexpression of PLP1 protein.
  genes:
  - preferred_term: PLP1
    term:
      id: hgnc:9086
      label: PLP1
  molecular_functions:
  - preferred_term: structural constituent of myelin sheath
    term:
      id: GO:0019911
      label: structural constituent of myelin sheath
  downstream:
  - target: Abnormal Cholesterol and Lipid Trafficking
    description: >
      Excess PLP from duplication sequesters cholesterol in lysosomal
      compartments and disrupts lipid raft and sphingolipid trafficking.
    causal_link_type: DIRECT
  - target: Oligodendrocyte Maturation Arrest and Process Retraction
    description: >
      PLP1 overexpression can arrest oligodendrocyte maturation and reduce
      oligodendroglial process extension before normal myelin formation.
    causal_link_type: DIRECT
  - target: Microglial Activation in Diseased White Matter
    description: >
      PMD tissue and models with PLP1 duplications can show microglial activation
      during disease progression.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PLP gene duplications are the most common cause of Pelizaeus-Merzbacher disease"
    explanation: Confirms PLP1 duplications as the most common mutation type.
- name: Abnormal Cholesterol and Lipid Trafficking
  description: >
    Excess PLP1 from gene duplication causes sequestration of cholesterol in
    lysosomal compartments, resulting in abnormal trafficking of lipid rafts
    and sphingolipids, leading to oligodendrocyte injury and death.
  downstream:
  - target: Defective CNS Myelination
    description: >
      Lipid-trafficking disruption injures oligodendrocytes and compromises
      myelin assembly.
    causal_link_type: DIRECT
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: lipid transport
    term:
      id: GO:0006869
      label: lipid transport
  locations:
  - preferred_term: central nervous system white matter
    term:
      id: UBERON:0003544
      label: brain white matter
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Increased levels of PLP may lead to sequestration of cholesterol in the lysosomal compartments, resulting in abnormal cellular trafficking of lipid rafts and sphingolipids that are normally sorted out of the Golgi compartments, and this in turn may result in oligodendrocyte injury and early oligodendroglial death"
    explanation: Describes the mechanism by which PLP1 overexpression leads to oligodendrocyte dysfunction through lipid trafficking defects.
- name: Oligodendrocyte Maturation Arrest and Process Retraction
  description: >
    PLP1 overexpression in oligodendrocytes can prevent normal maturation and
    limit oligodendroglial process extension. This reduces the ability of
    oligodendrocytes to ensheath axons and contributes to CNS hypomyelination.
  downstream:
  - target: Defective CNS Myelination
    description: >
      Maturation-arrested oligodendrocytes cannot generate the normal myelin
      sheath needed for CNS white matter development.
    causal_link_type: DIRECT
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: oligodendrocyte differentiation
    term:
      id: GO:0048709
      label: oligodendrocyte differentiation
  locations:
  - preferred_term: central nervous system white matter
    term:
      id: UBERON:0003544
      label: brain white matter
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Some studies show evidence of oligodendrocyte maturation arrest and eventual cell death, associated with swelling of the Golgi apparatus"
    explanation: >
      PLP1-overexpressing mouse models show oligodendrocyte maturation arrest,
      supporting this duplication-specific pathophysiology branch.
- name: PLP1 Null Mutation Causing Axon-Glial Support Failure
  description: >
    PLP1 deletions and null mutations can leave myelin structure relatively
    preserved compared with toxic gain-of-function variants, but loss of PLP
    disrupts axon-glial support and predisposes to axonal injury and peripheral
    neuropathy.
  genes:
  - preferred_term: PLP1
    term:
      id: hgnc:9086
      label: PLP1
  molecular_functions:
  - preferred_term: structural constituent of myelin sheath
    term:
      id: GO:0019911
      label: structural constituent of myelin sheath
  biological_processes:
  - preferred_term: CNS myelination
    term:
      id: GO:0022010
      label: central nervous system myelination
  downstream:
  - target: Peripheral Nerve Demyelination and Axonal Injury
    description: >
      PLP1 null states are especially associated with peripheral demyelinating
      neuropathy and axonal injury.
    causal_link_type: DIRECT
  - target: Defective CNS Myelination
    description: >
      PLP1 null states remain in the PLP1-related hypomyelinating spectrum, but
      typically produce milder CNS involvement than toxic missense or dosage
      gain mechanisms.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - reduced PLP-dependent axon-glial support
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  locations:
  - preferred_term: central nervous system white matter
    term:
      id: UBERON:0003544
      label: brain white matter
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "both PLP-deficient mice and patients with PLP null mutations show evidence of axonal injury"
    explanation: >
      Supports loss of PLP-dependent axon-glial support as a null-mutation
      mechanism distinct from toxic misfolding or overexpression.
- name: Peripheral Nerve Demyelination and Axonal Injury
  description: >
    In PLP1 null syndrome, peripheral nerves can show demyelinating neuropathy
    with axonal injury, creating a mutation-class-specific path to the
    peripheral neuropathy phenotype.
  downstream:
  - target: Peripheral Neuropathy
    description: >
      Peripheral demyelination and axonal injury produce the clinically observed
      demyelinating peripheral neuropathy in PLP1 null syndrome.
    causal_link_type: DIRECT
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  biological_processes:
  - preferred_term: peripheral nervous system myelination
    term:
      id: GO:0022011
      label: myelination in peripheral nervous system
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The PLP1 null phenotype represents another syndrome later described by Garbern and colleagues, and is characterized by complicated spastic paraplegia, with mild to moderate demyelinating peripheral neuropathy and axonal injury"
    explanation: >
      Directly links the PLP1 null subtype to demyelinating peripheral
      neuropathy and axonal injury.
- name: Defective CNS Myelination
  description: >
    Regardless of the specific PLP1 mutation type, the downstream consequence is a
    failure of normal CNS myelination. Oligodendrocytes either die before forming
    myelin or produce structurally abnormal myelin sheaths. MRI shows diffuse
    hypomyelination of the cerebral white matter.
  downstream:
  - target: Leukodystrophy
    description: >
      Diffuse CNS hypomyelination produces the defining leukodystrophy and MRI
      phenotype.
    causal_link_type: DIRECT
  - target: Delayed Motor Development
    description: >
      Early CNS hypomyelination disrupts motor pathway maturation and causes
      delayed or unachieved motor milestones.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired maturation of central motor pathways
  - target: Nystagmus
    description: >
      Hypomyelinating white matter disease is associated with early ocular motor
      dysfunction and pendular nystagmus.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired ocular motor pathway myelination
  - target: Hypotonia
    description: >
      Early CNS hypomyelination contributes to the initial axial hypotonia seen
      in classic and connatal PMD.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired central motor pathway function
  - target: Head Titubation
    description: >
      The same early neurologic dysfunction that produces nystagmus is associated
      with head tremor or titubation in classic PMD.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired cerebellar and ocular motor pathway function
  - target: Progressive Spasticity
    description: >
      Progressive involvement of long motor tracts and corticospinal pathways
      produces spasticity after the initial hypotonic phase.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - corticospinal tract dysfunction
  - target: Ataxia
    description: >
      Cerebellar and central white matter involvement contributes to ataxia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - cerebellar pathway dysfunction
  - target: Intellectual Disability
    description: >
      Diffuse developmental hypomyelination contributes to cognitive impairment.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired cerebral white matter network development
  - target: Dysarthria
    description: >
      Spastic, cerebellar, and corticobulbar pathway involvement contributes to
      dysarthria.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - corticobulbar and cerebellar pathway dysfunction
  - target: Dysphagia
    description: >
      Severe neurologic involvement can impair swallowing and require feeding
      support.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - corticobulbar pathway dysfunction
  - target: Choreoathetosis
    description: >
      Extrapyramidal pathway involvement contributes to choreoathetoid movements.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - basal ganglia and extrapyramidal pathway dysfunction
  - target: Dystonia
    description: >
      Extrapyramidal involvement in PMD can manifest as dystonia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - basal ganglia and extrapyramidal pathway dysfunction
  - target: Seizures
    description: >
      Severe CNS involvement can predispose to seizures, particularly later in
      the course or in severe forms.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Optic Atrophy
    description: >
      CNS white matter and visual pathway involvement can culminate in optic
      atrophy.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - visual pathway involvement
  - target: Laryngeal Stridor
    description: >
      Brainstem and corticobulbar dysfunction in connatal PMD contributes to
      laryngeal stridor.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - brainstem and laryngeal motor pathway dysfunction
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: CNS myelination
    term:
      id: GO:0022010
      label: central nervous system myelination
  locations:
  - preferred_term: cerebral white matter
    term:
      id: UBERON:0002437
      label: cerebral hemisphere white matter
  evidence:
  - reference: PMID:27882623
    reference_title: "Concise Review: Stem Cell-Based Treatment of Pelizaeus-Merzbacher Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "all forms of the disease result in central hypomyelination, associated in most cases with early neurological dysfunction, progressive deterioration, and ultimately death"
    explanation: Confirms that all forms of PMD share the feature of central hypomyelination.
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There is a marked deficiency of myelin, particularly in deeper cerebral structures, but relative myelin preservation in areas surrounding blood vessels, providing the classic tigroid appearance of PMD histopathology"
    explanation: Describes the characteristic histopathological pattern of myelin deficiency in PMD.
- name: Microglial Activation in Diseased White Matter
  description: >
    Microglial activation has been reported in PMD patient biopsies and animal
    models with PLP1 missense mutations or duplications, indicating innate
    immune activation can accompany disease progression.
  downstream:
  - target: Defective CNS Myelination
    description: >
      Neuroinflammatory activation is a superimposed disease-progression process
      associated with the dysmyelinating white matter state.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  cell_types:
  - preferred_term: microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  biological_processes:
  - preferred_term: neuroinflammatory response
    term:
      id: GO:0150076
      label: neuroinflammatory response
  locations:
  - preferred_term: central nervous system white matter
    term:
      id: UBERON:0003544
      label: brain white matter
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "microglial activation has been reported in biopsies of patients with both PLP1 missense mutations and duplications, as well as in animal models with similar mutations"
    explanation: >
      Review evidence supports microglial activation as a neuroinflammatory
      component in PMD tissues and matching animal models.
- name: Iron-Dependent Oligodendrocyte Death (Ferroptosis)
  description: >
    PLP1-mutant oligodendrocytes exhibit hallmarks of ferroptosis including lipid
    peroxidation, abnormal iron metabolism, and hypersensitivity to free iron.
    Iron chelation with deferiprone rescues oligodendrocyte apoptosis and enables
    myelin formation in preclinical models, representing an additional death
    mechanism beyond ER stress-mediated apoptosis.
  downstream:
  - target: Defective CNS Myelination
    description: >
      Iron-dependent oligodendrocyte death reduces oligodendrocyte survival and
      myelin formation.
    causal_link_type: DIRECT
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: ferroptosis
    term:
      id: GO:0097707
      label: ferroptosis
  locations:
  - preferred_term: central nervous system white matter
    term:
      id: UBERON:0003544
      label: brain white matter
  evidence:
  - reference: PMID:31585094
    reference_title: "Oligodendrocyte Death in Pelizaeus-Merzbacher Disease Is Rescued by Iron Chelation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Mutant oligodendrocytes demonstrated key hallmarks of ferroptosis including lipid peroxidation, abnormal iron metabolism, and hypersensitivity to free iron"
    explanation: iPSC-derived PLP1-mutant oligodendrocytes show ferroptosis hallmarks including lipid peroxidation and abnormal iron metabolism.
  - reference: PMID:31585094
    reference_title: "Oligodendrocyte Death in Pelizaeus-Merzbacher Disease Is Rescued by Iron Chelation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "systemic treatment of Plp1 mutant Jimpy mice with deferiprone, a small molecule iron chelator, reduced oligodendrocyte apoptosis and enabled myelin formation"
    explanation: Iron chelation rescues oligodendrocyte death and enables myelination in the jimpy mouse model.
phenotypes:
- name: Nystagmus
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Often the earliest sign, appearing in the first weeks to months of life. Typically pendular nystagmus.
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "it is characterized by pendular nystagmus, head tremor, and systemic hypotonia"
    explanation: Nystagmus is described as one of the cardinal features of prototypic PMD.
- name: Hypotonia
  category: Neurological
  frequency: VERY_FREQUENT
  notes: Early hypotonia that typically transitions to spasticity with age.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:20301361
    reference_title: "PLP1-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PMD typically manifests in infancy or early childhood with nystagmus, hypotonia, and cognitive impairment"
    explanation: GeneReviews confirms hypotonia as a typical early manifestation of PMD.
- name: Progressive Spasticity
  category: Neurological
  frequency: VERY_FREQUENT
  notes: Develops after initial hypotonic phase, often becoming the predominant motor finding.
  sequelae:
  - target: Scoliosis
    description: >
      Chronic spasticity, impaired trunk control, and reduced mobility predispose
      to scoliosis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired trunk control
    - reduced mobility
  phenotype_term:
    preferred_term: Progressive spasticity
    term:
      id: HP:0002191
      label: Progressive spasticity
  evidence:
  - reference: PMID:20301361
    reference_title: "PLP1-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the findings progress to severe spasticity and ataxia"
    explanation: GeneReviews confirms progressive spasticity as a major feature of PMD.
- name: Ataxia
  category: Neurological
  frequency: FREQUENT
  notes: Cerebellar ataxia contributing to motor impairment and gait difficulties.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "affected patients manifest some combination of mental retardation, choreoathetosis, dystonia, cerebellar ataxia and long tract signs"
    explanation: Cerebellar ataxia is listed among the neurological manifestations of PMD.
- name: Intellectual Disability
  category: Neurological
  frequency: FREQUENT
  notes: Variable severity; ranges from mild to severe depending on PMD form.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:20301361
    reference_title: "PLP1-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PMD typically manifests in infancy or early childhood with nystagmus, hypotonia, and cognitive impairment"
    explanation: Cognitive impairment is a core feature of PMD per GeneReviews.
- name: Dysarthria
  category: Neurological
  frequency: FREQUENT
  notes: Speech difficulties due to spasticity and cerebellar involvement.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "spasticity of the lower extremities that can be isolated, or co-exist with varying degrees of cognitive impairment, nystagmus, ataxia, dysarthria and spastic urinary bladder"
    explanation: Dysarthria is listed among the neurological features associated with PLP1-related disorders.
- name: Dysphagia
  category: Neurological
  notes: Severe bulbar involvement may require feeding support such as gastrostomy.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:20301361
    reference_title: "PLP1-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "gastrostomy for individuals with severe dysphagia"
    explanation: >
      GeneReviews includes dysphagia severe enough to require gastrostomy among
      PLP1-related disorder manifestations managed clinically.
- name: Head Titubation
  category: Neurological
  frequency: FREQUENT
  notes: Involuntary rhythmic head movement, characteristic of classic PMD.
  phenotype_term:
    preferred_term: Head titubation
    term:
      id: HP:0002599
      label: Head titubation
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "it is characterized by pendular nystagmus, head tremor, and systemic hypotonia"
    explanation: Head tremor (titubation) is described as a cardinal feature of prototypic PMD.
- name: Leukodystrophy
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: MRI shows diffuse hypomyelination of cerebral white matter.
  phenotype_term:
    preferred_term: Leukodystrophy
    term:
      id: HP:0002415
      label: Leukodystrophy
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI subsequently revealed overt hypomyelination, as reflected by the failure of PMD patients to develop the expected developmental increase in T1 and decrease in T2 signals characteristic of myelin maturation"
    explanation: Describes the characteristic MRI finding of hypomyelination in PMD.
- name: Delayed Motor Development
  category: Neurological
  frequency: VERY_FREQUENT
  notes: Significant delays in achieving motor milestones; many patients never walk independently.
  phenotype_term:
    preferred_term: Delayed gross motor development
    term:
      id: HP:0002194
      label: Delayed gross motor development
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Classic PMD presents before the first year of age, with nystagmus, slowly acquired or unachieved motor milestones, and significant axial hypotonia"
    explanation: Delayed or unachieved motor milestones are a core feature of classic PMD.
- name: Choreoathetosis
  category: Neurological
  frequency: FREQUENT
  notes: Involuntary movements including choreoathetosis and dystonia.
  phenotype_term:
    preferred_term: Choreoathetosis
    term:
      id: HP:0001266
      label: Choreoathetosis
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "affected patients manifest some combination of mental retardation, choreoathetosis, dystonia, cerebellar ataxia and long tract signs"
    explanation: Choreoathetosis is listed among the neurological manifestations of PMD.
- name: Dystonia
  category: Neurological
  notes: Extrapyramidal motor involvement may include dystonia.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "affected patients manifest some combination of mental retardation, choreoathetosis, dystonia, cerebellar ataxia and long tract signs"
    explanation: Dystonia is listed among neurological manifestations of PMD.
- name: Seizures
  category: Neurological
  frequency: OCCASIONAL
  notes: Seizures may occur, particularly in connatal form. Typically responsive to antiepileptic agents.
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Optic atrophy and seizures may occur later in the course, although seizures are uncommon, and typically treatable"
    explanation: Seizures occur but are uncommon and typically treatable in classic PMD.
- name: Optic Atrophy
  category: Ophthalmological
  frequency: OCCASIONAL
  notes: May develop later in disease course, particularly in connatal form.
  phenotype_term:
    preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Optic atrophy and seizures may occur later in the course, although seizures are uncommon, and typically treatable"
    explanation: Optic atrophy is described as a later-onset feature of classic PMD.
- name: Laryngeal Stridor
  category: Respiratory
  frequency: OCCASIONAL
  notes: Characteristic of connatal form. Due to laryngeal involvement.
  phenotype_term:
    preferred_term: Laryngeal stridor
    term:
      id: HP:0010307
      label: Stridor
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Babies with connatal PMD manifest extrapyramidal signs, laryngeal stridor, feeding difficulties and optic atrophy"
    explanation: Laryngeal stridor is a characteristic feature of connatal PMD.
- name: Scoliosis
  category: Musculoskeletal
  frequency: FREQUENT
  notes: Develops as a consequence of spasticity and immobility.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:20301361
    reference_title: "PLP1-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "individuals with scoliosis benefit from proper wheelchair seating and physical therapy; surgery may be required for severe scoliosis"
    explanation: GeneReviews describes scoliosis management as part of PMD care, confirming it as a recognized complication.
- name: Peripheral Neuropathy
  category: Neurological
  frequency: OCCASIONAL
  notes: Primarily associated with PLP1 null mutations and deletions. Demyelinating type.
  phenotype_term:
    preferred_term: Demyelinating peripheral neuropathy
    term:
      id: HP:0007108
      label: Demyelinating peripheral neuropathy
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The PLP1 null phenotype represents another syndrome later described by Garbern and colleagues, and is characterized by complicated spastic paraplegia, with mild to moderate demyelinating peripheral neuropathy and axonal injury"
    explanation: Demyelinating peripheral neuropathy is characteristic of PLP1 null syndrome.
genetic:
- name: PLP1
  association: Causative
  gene_term:
    preferred_term: PLP1
    term:
      id: hgnc:9086
      label: PLP1
  notes: >
    PMD is caused by mutations in the PLP1 gene (Xq22.2), which encodes proteolipid
    protein 1, the major protein component of CNS myelin. PLP1 duplications account
    for 50-75% of cases, point mutations for about 20%, and deletions for less than 5%.
    The PMD OMIM identifier is 312080.
  variants:
  - name: PLP1 duplication
    description: >
      Genomic duplication of the PLP1 locus, the most common mutation type (50-75%
      of cases). Leads to PLP1 overexpression and often the classic PMD phenotype;
      higher-order and complex copy-number gains may increase severity.
    evidence:
    - reference: PMID:29478609
      reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "PLP gene duplications are the most common cause of Pelizaeus-Merzbacher disease"
      explanation: Confirms PLP1 duplications as the predominant cause of PMD.
  - name: PLP1 point mutations
    description: >
      Missense mutations causing protein misfolding. Severity depends on specific
      residue; some cause severe connatal form, others milder phenotypes.
    evidence:
    - reference: PMID:29478609
      reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Point mutations account for another 20% of cases, and are associated with highly variable phenotypes; these can vary from clinically mild to severe connatal forms"
      explanation: Describes the prevalence and clinical variability of PLP1 point mutations.
  - name: PLP1 splice-altering variants
    description: >
      Non-coding intronic splice donor, acceptor, branch-site, and splice
      regulatory variants can disrupt PLP1/DM20 precursor RNA splicing. These
      variants contribute to clinically heterogeneous PMD presentations.
    evidence:
    - reference: PMID:29478609
      reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Mutations in non-coding regions that disrupt the normal splicing of PLP1/DM20 precursor RNA are another cause of PMD"
      explanation: Describes splice-altering PLP1 variants as an additional PMD mutation class.
  - name: PLP1 deletion
    description: >
      Complete loss of PLP1 expression. Paradoxically causes milder CNS disease
      but with added peripheral neuropathy and axonal injury, defining the PLP1
      null syndrome branch of the PLP1-related disorder spectrum.
    evidence:
    - reference: PMID:29478609
      reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "PLP1 deletions are less common, accounting for <5% of identified cases; paradoxically, these are associated with milder phenotypes"
      explanation: Confirms that PLP1 deletions cause a paradoxically milder phenotype.
  evidence:
  - reference: PMID:15627202
    reference_title: "PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both PMD and SPG2 are caused by mutations in the proteolipid protein 1 (PLP1) gene, which encodes a major component of CNS myelin proteins"
    explanation: Confirms PLP1 as the causative gene for PMD.
  - reference: PMID:17115121
    reference_title: "Pelizaeus-Merzbacher disease: Genetic and cellular pathogenesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pelizaeus-Merzbacher disease (PMD) and the allelic spastic paraplegia type 2 (SPG2) arise from mutations in the X-linked gene encoding myelin proteolipid protein (PLP)"
    explanation: Confirms the genetic basis of PMD in PLP1 mutations.
  - reference: CGGV:assertion_c1a44c5f-744e-4d02-a08f-e7c687531b21-2018-03-07T110000.000Z
    reference_title: "PLP1 / Pelizeaus-Merzbacher spectrum disorder (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PLP1 | HGNC:9086 | Pelizeaus-Merzbacher spectrum disorder | MONDO:0010714 | XL | Definitive"
    explanation: ClinGen classifies the PLP1-Pelizeaus-Merzbacher spectrum disorder gene-disease relationship as definitive with X-linked inheritance.
treatments:
- name: Supportive Care
  description: >
    No cure exists for PMD. Treatment is supportive and includes physical therapy,
    occupational therapy, and management of spasticity with medications such as
    baclofen. Seizure management with antiepileptic drugs when needed.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301361
    reference_title: "PLP1-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "routine management of spasticity including physical therapy, exercise, medications (baclofen, diazepam, tizanidine), orthotics, and surgery for joint contractures"
    explanation: GeneReviews describes the multidisciplinary supportive care approach for PMD management.
- name: Physical Therapy
  description: >
    Rehabilitation to maintain mobility, prevent contractures, and optimize
    functional abilities.
  treatment_term:
    preferred_term: Physical Therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  evidence:
  - reference: PMID:20301361
    reference_title: "PLP1-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "physical and occupational therapy for ataxia with adaptive devices as needed"
    explanation: GeneReviews recommends physical and occupational therapy as part of PMD management.
- name: Stem Cell Transplantation (Investigational)
  description: >
    Neural stem cell and glial progenitor cell transplantation are being investigated
    as potential therapies for PMD, aiming to provide donor-derived oligodendrocytes
    capable of myelinating host axons.
  treatment_term:
    preferred_term: neural stem cell transplantation
    term:
      id: MAXO:0000016
      label: cellular therapy
  evidence:
  - reference: PMID:27882623
    reference_title: "Concise Review: Stem Cell-Based Treatment of Pelizaeus-Merzbacher Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PMD and similar hypomyelinating disorders are attractive therapeutic targets for neural stem cell and glial progenitor cell transplantation, efforts at which are now underway in a number of research centers"
    explanation: Reviews the rationale and ongoing efforts for stem cell-based therapy in PMD.
  target_mechanisms:
  - target: Defective CNS Myelination
    treatment_effect: MODULATES
    description: >-
      Transplanted neural stem cells and glial progenitors can differentiate
      into donor-derived oligodendrocytes capable of myelinating host axons,
      directly targeting the defective CNS myelination that is the central
      phenotypic consequence of PLP1 pathology.
- name: PLP1 Antisense Oligonucleotide Therapy (Investigational)
  description: >
    Antisense oligonucleotides (ASOs) targeting PLP1 mRNA to suppress expression
    have shown dramatic preclinical efficacy in the jimpy mouse model, fully
    restoring oligodendrocyte numbers, myelination, motor function, and lifespan.
    This approach exploits the observation that PLP1-null individuals have milder
    disease than those with gain-of-function mutations.
  treatment_term:
    preferred_term: antisense oligonucleotide therapy
    term:
      id: MAXO:0001593
      label: antisense oligonucleotide inhibitor therapy
  evidence:
  - reference: PMID:32610343
    reference_title: "Suppression of proteolipid protein rescues Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Administration of a single dose of Plp1-targeting antisense oligonucleotides in postnatal jimpy mice fully restored oligodendrocyte numbers, increased myelination, improved motor performance, normalized respiratory function and extended lifespan up to an eight-month end point"
    explanation: Landmark Nature study demonstrating that ASO-mediated PLP1 suppression rescues the jimpy mouse model of severe PMD.
  target_mechanisms:
  - target: PLP1 Gene Duplication Causing Overexpression
    treatment_effect: INHIBITS
    description: >-
      PLP1-targeting ASOs suppress PLP1 mRNA levels, reducing the toxic
      overexpression of PLP1 protein caused by gene duplication and relieving
      the unfolded protein response-driven oligodendrocyte apoptosis.
  - target: PLP1 Missense Mutation Causing Protein Misfolding
    treatment_effect: INHIBITS
    description: >-
      ASO-mediated knockdown of PLP1 mRNA also reduces the load of misfolded
      PLP1 protein in oligodendrocytes bearing missense mutations, attenuating
      UPR activation and oligodendrocyte apoptosis.
- name: Deferiprone Iron Chelation (Investigational)
  description: >
    Iron chelation with deferiprone is an investigational strategy targeting
    iron-dependent oligodendrocyte death. In Plp1 mutant Jimpy mice, systemic
    deferiprone reduced oligodendrocyte apoptosis and enabled myelin formation.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: deferiprone
      term:
        id: CHEBI:68554
        label: deferiprone
  target_mechanisms:
  - target: Iron-Dependent Oligodendrocyte Death (Ferroptosis)
    treatment_effect: INHIBITS
    description: >
      Deferiprone chelates iron and reduces the iron-dependent oligodendrocyte
      death branch of the PMD pathograph.
  evidence:
  - reference: PMID:31585094
    reference_title: "Oligodendrocyte Death in Pelizaeus-Merzbacher Disease Is Rescued by Iron Chelation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "systemic treatment of Plp1 mutant Jimpy mice with deferiprone, a small molecule iron chelator, reduced oligodendrocyte apoptosis and enabled myelin formation"
    explanation: Preclinical mouse evidence supports deferiprone as an investigational iron-chelation approach for PMD ferroptosis.
- name: Genetic Counseling
  description: >
    Counseling for X-linked inheritance, carrier testing, recurrence risk, and
    prenatal or preimplantation genetic testing once the familial PLP1 pathogenic
    variant is known.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301361
    reference_title: "PLP1-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Once the PLP1 pathogenic variant has been identified in an affected family member, heterozygote detection and prenatal and preimplantation genetic testing are possible"
    explanation: GeneReviews supports genetic counseling and reproductive testing for families with PLP1-related disorders.
- name: Speech Therapy
  description: >
    Speech therapy is part of multidisciplinary supportive rehabilitation for
    PMD, particularly when communication or bulbar dysfunction contributes to
    disability.
  treatment_term:
    preferred_term: speech therapy
    term:
      id: MAXO:0000930
      label: speech therapy
  evidence:
  - reference: DOI:10.18231/j.ijn.2024.037
    reference_title: "A rare case of radiologically diagnosed Pelizaeus-Merzbacher's disease (PMD) in a female infant"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Management involved a multidisciplinary approach, incorporating play therapy, speech therapy, physiotherapy for spasticity, and behavioral therapy"
    explanation: Case-report evidence lists speech therapy as part of PMD multidisciplinary management.
diagnosis:
- name: Brain MRI
  description: >
    MRI reveals diffuse hypomyelination with failure to develop normal T1 and T2
    signal maturation patterns. The hallmark is absence of normal myelination
    progression on serial imaging.
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI subsequently revealed overt hypomyelination, as reflected by the failure of PMD patients to develop the expected developmental increase in T1 and decrease in T2 signals characteristic of myelin maturation"
    explanation: Describes the characteristic MRI pattern used to diagnose PMD.
- name: PLP1 Molecular Genetic Testing
  description: >
    Diagnosis is confirmed by identification of a hemizygous pathogenic variant
    in PLP1 including duplications, point mutations, or deletions. Testing
    methods include MLPA, array CGH, and sequencing.
  evidence:
  - reference: PMID:20301361
    reference_title: "PLP1-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of a PLP1-related disorder is established in a male proband by identification of a hemizygous pathogenic variant involving PLP1"
    explanation: GeneReviews confirms that molecular genetic testing of PLP1 establishes the diagnosis.
animal_models:
- species: Mouse
  genotype: Plp1jp (jimpy)
  description: >
    The jimpy mouse carries a point mutation in Plp1, modeling severe connatal PMD.
    Characterized by extensive oligodendrocyte loss, severe hypomyelination,
    seizures, tremor, and early death at 3-4 weeks of age. Used extensively for
    preclinical therapeutic studies including ASO and CRISPR approaches.
  associated_phenotypes:
  - Severe hypomyelination
  - Oligodendrocyte apoptosis
  - Tremor
  - Seizures
  - Early lethality
  evidence:
  - reference: PMID:32610343
    reference_title: "Suppression of proteolipid protein rescues Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "using CRISPR-Cas9 to suppress Plp1 expression in the jimpy (Plp1jp) point-mutation mouse model of severe PMD, increased myelination and restored nerve conduction velocity, motor function and lifespan of the mice to wild-type levels"
    explanation: Describes the jimpy mouse model and its rescue through PLP1 suppression.
- species: Mouse
  genotype: Plp1 transgenic (overexpression)
  description: >
    Transgenic mice overexpressing Plp1 model the PLP1 duplication form of PMD.
    Show severe demyelination, oligodendrocyte death, and motor dysfunction
    proportional to the level of PLP1 overexpression.
  associated_phenotypes:
  - Demyelination
  - Oligodendrocyte maturation arrest
  - Motor dysfunction
  evidence:
  - reference: PMID:24680886
    reference_title: "Progesterone antagonist therapy in a Pelizaeus-Merzbacher mouse model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We used a Plp1 transgenic PMD mouse model to test the therapeutic effect of Lonaprisan, an antagonist of the nuclear progesterone receptor, in lowering Plp1 mRNA overexpression"
    explanation: Describes the Plp1 transgenic mouse model used to study duplication-based PMD.
  - reference: PMID:21401588
    reference_title: "Axon-glial interaction in the CNS: what we have learned from mouse models of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Animal models of these diseases, particularly models lacking or overexpressing Plp1, have shed light on the interplay between axons and oligodendrocytes, and how one component influences the other"
    explanation: Reviews mouse models of PMD including overexpression models and their contributions to understanding axon-glial interactions.
clinical_trials:
- name: NCT05659901
  phase: NOT_APPLICABLE
  status: RECRUITING
  description: >
    Rocket observational study characterizing longitudinal PLP1 protein,
    disease-related CSF and blood biomarkers, neuroimaging parameters, and
    clinical, participant, and caregiver-reported outcomes in participants with
    Pelizaeus-Merzbacher disease to support therapy development.
  evidence:
  - reference: clinicaltrials:NCT05659901
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The purpose of the study is to prospectively assess longitudinal changes in proteolipid protein 1 (PLP1) protein, disease-related biomarkers in cerebral spinal fluid (CSF) and blood, neuroimaging parameters relevant to Pelizaeus-Merzbacher disease (PMD) and longitudinal changes in performance on clinical, participant, and caregiver-reported outcome assessments to inform the development of therapies for PMD."
    explanation: >
      Observational PMD natural-history and biomarker study identified by the
      Falcon research report.
- name: NCT06150716
  phase: PHASE_I
  status: RECRUITING
  description: >
    Orbit study evaluating intrathecal ION356, a PLP1-targeting antisense
    oligonucleotide, in pediatric males with genetically confirmed PLP1
    duplication PMD. Multiple ascending dose design with 48-week treatment
    and 109-week long-term extension.
  evidence:
  - reference: clinicaltrials:NCT06150716
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The primary purpose of this study is to evaluate the safety and tolerability of ION356"
    explanation: Phase 1b trial of PLP1-lowering ASO therapy for PMD with PLP1 duplication.
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
datasets: []
references:
- reference: PMID:20301361
  title: "PLP1-Related Disorders."
  tags:
  - GeneReviews
  findings: []

📚

References & Deep Research

References

1

PMID:20301361

PLP1-Related Disorders.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 27 citations 2026-04-25T22:26:07.606108

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Pelizaeus-Merzbacher Disease
MONDO ID: (if available)
Category: Genetic

Research Objectives

Please provide a comprehensive research report on Pelizaeus-Merzbacher Disease covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Disease Characteristics Research Report: Pelizaeus–Merzbacher Disease (PMD)

Target disease

Disease name: Pelizaeus–Merzbacher disease (PMD)
Category: Genetic leukodystrophy / hypomyelinating leukodystrophy
Primary causal gene: PLP1 (proteolipid protein 1)

1. Disease information

1.1 Overview (current understanding)

Pelizaeus–Merzbacher disease (PMD) is a progressive X-linked hypomyelinating leukodystrophy characterized by early neurologic onset (often infancy), with features such as nystagmus and developmental delay and later progression to spasticity/quadriplegia and ataxia. (rogac2023opticalgenomemapping pages 1-2)

A modern terminology used in parts of the literature is hypomyelinating leukodystrophy type 1 (HLD1) for the PLP1-associated disorder. (fukushima2024crisprcasrxmediatedknockdownof pages 1-2)

1.2 Key identifiers (as available in the retrieved sources)

OMIM (disease): PMD 312080 (reported explicitly) (rogac2023opticalgenomemapping pages 1-2)
OMIM (gene): PLP1 300401 (reported explicitly) (rogac2023opticalgenomemapping pages 1-2)
MeSH: Pelizaeus-Merzbacher Disease (D020371) (ClinicalTrials.gov condition browse) (NCT05659901 chunk 1)
MONDO: Open Targets lists MONDO_0010714 (Pelizeaus-Merzbacher spectrum disorder) and subtype MONDO terms for connatal/transitional/classic PMD and PMD in female carriers. (NCT05659901 chunk 1)

Not available in the retrieved full text for this run: Orphanet ID and ICD-10/ICD-11 codes were not present in the available context; they should be added from Orphanet/WHO ICD sources during curation.

1.3 Synonyms / alternative names

Pelizaeus–Merzbacher disease (PMD) (rogac2023opticalgenomemapping pages 1-2)
Hypomyelinating leukodystrophy type 1 (HLD1) (fukushima2024crisprcasrxmediatedknockdownof pages 1-2)
PLP1-related disorders (umbrella term often including PMD and SPG2) (wolf2025plp1relateddisordersa pages 3-6)

1.4 Evidence source type

This report integrates aggregated disease-level sources (e.g., clinical genetics summaries and trial registry records) with individual-level case reports/series and cellular modeling studies. (wolf2025plp1relateddisordersa pages 3-6, johari2023arehabilitationjourney pages 1-2, fukushima2024crisprcasrxmediatedknockdownof pages 1-2, NCT05659901 chunk 1)

2. Etiology

2.1 Primary causal factors

PMD is primarily caused by pathogenic variants in PLP1 (Xq22) that disrupt CNS myelin formation, including copy-number gains (duplications/triplications), sequence variants (missense/nonsense/splice/indels), and deletions. (wolf2025plp1relateddisordersa pages 3-6, rogac2023opticalgenomemapping pages 1-2, akkus2023dörtailedenpelizaeusmerzbacher pages 1-2)

Quantitative variant-class distribution (recent/compiled sources): - Xq22 microduplications/PLP1 duplications: ~60–70% (akkus2023dörtailedenpelizaeusmerzbacher pages 1-2) - Point mutations: ~10–25% (akkus2023dörtailedenpelizaeusmerzbacher pages 1-2) - Deletions: ~5–10% (akkus2023dörtailedenpelizaeusmerzbacher pages 1-2)

A separate 2023 genetics report also states that PLP1 duplications account for ~50–75% of clinically manifest disease-causing variants. (rogac2023opticalgenomemapping pages 1-2)

2.2 Risk factors

Genetic: X-linked inheritance; carrier females have a 50% transmission risk per pregnancy. (wolf2025plp1relateddisorders pages 17-19, rogac2023opticalgenomemapping pages 1-2)
Sex: Typically affects males more severely; females can be affected, in part due to skewed X-inactivation (clinical observation in a 2024 report). (dharni2024ararecase pages 1-2)

2.3 Protective factors

No protective genetic alleles or environmental protective factors were identified in the retrieved evidence for this run.

2.4 Gene–environment interactions

No gene–environment interactions were identified in the retrieved evidence for this run.

3. Phenotypes

3.1 Core phenotype spectrum (symptoms/signs)

Commonly reported features include developmental delay, hypotonia, nystagmus, spasticity (paraparesis or quadriplegia), ataxia, dysarthria, dysphagia, and visual system involvement (e.g., optic atrophy). (johari2023arehabilitationjourney pages 1-2, manzke2025clinicalcharacteristicsof pages 1-2, rogac2023opticalgenomemapping pages 1-2)

A 2025 clinical report of classic PMD lists: “developmental delays, nystagmus, spastic paraparesis, optic atrophy, dysphagia, appendicular ataxia, and progressive head tremor.” (Manzke et al.; acceptance 2024-10-30; URL https://doi.org/10.1038/s41439-024-00306-8) (manzke2025clinicalcharacteristicsof pages 1-2)

A 2024 female-infant report emphasizes neuroregression and imaging-driven diagnosis in resource-limited settings and notes supportive therapy components. (dharni2024ararecase pages 1-2)

3.2 Subtypes and severity (current clinical framing)

A clinically used severity framing described in a 2023 rehabilitation-focused report includes connatal (type I), transitional (type II), and classic (type III) PMD, with SPG2 (spastic paraplegia type 2) as a milder allelic end of the PLP1-related spectrum. (johari2023arehabilitationjourney pages 1-2)

3.3 Age of onset, progression, and course

Classic PMD: often presents in the first year of life, including neonatal hypotonia and failure to meet motor milestones, with progressive severe spasticity; life expectancy is commonly between adolescence and young adulthood. (johari2023arehabilitationjourney pages 1-2)
Connatal PMD: neonatal onset with severe hypotonia, extrapyramidal signs and laryngeal stridor; high disability and early-childhood mortality from secondary complications. (johari2023arehabilitationjourney pages 1-2)
Trajectory note: nystagmus may lessen over time while other motor/cognitive impairments worsen. (manzke2025clinicalcharacteristicsof pages 1-2)

3.4 Quality-of-life impact

Available sources emphasize major functional dependence and need for long-term multidisciplinary management, including mobility limitations (often wheelchair use), communication impairment, and caregiver burden consistent with a chronic progressive neurodisability. (johari2023arehabilitationjourney pages 1-2, dharni2024ararecase pages 1-2)

3.5 Suggested HPO terms (non-exhaustive; for knowledge base mapping)

Based on phenotypes explicitly described in the retrieved sources: - Nystagmus; developmental delay; developmental regression; infantile hypotonia; spasticity; spastic paraparesis; spastic quadriplegia; ataxia; dysarthria; dysphagia; optic atrophy; tremor; dystonia; seizures; stridor. (johari2023arehabilitationjourney pages 1-2, manzke2025clinicalcharacteristicsof pages 1-2, dharni2024ararecase pages 1-2, rogac2023opticalgenomemapping pages 1-2)

4. Genetic / molecular information

4.1 Causal genes

PLP1 is the core causal gene for PMD. (rogac2023opticalgenomemapping pages 1-2, akkus2023dörtailedenpelizaeusmerzbacher pages 1-2)

4.2 Pathogenic variant types and functional consequences

Copy-number gains (duplications and more complex multiplications) - Tandem duplications involving Xq22 and PLP1 are common; triplication/partial triplication/quintuplication and complex rearrangements are also reported. (wolf2025plp1relateddisordersa pages 3-6)

Loss of function / deletions - Whole-gene deletions are reported as uncommon (“fewer than 2%” of PMD phenotypes). (wolf2025plp1relateddisordersa pages 3-6)

Missense variants and misfolding/ER stress - Severe connatal forms are described as often associated with missense variants that cause protein misfolding and oligodendrocyte toxicity. (johari2023arehabilitationjourney pages 1-2)

4.3 Genotype–phenotype correlations (clinically used heuristics)

A clinical genetics summary indicates that gene-targeted deletion/duplication analysis accounts for ~60–70% of pathogenic variants (largely duplications), while sequence analysis accounts for ~30–40% (missense/nonsense/splice/small indels). (wolf2025plp1relateddisordersa pages 3-6)

A 2023 rehabilitation-focused synthesis suggests: - Connatal PMD is “typically due to missense mutations” (johari2023arehabilitationjourney pages 1-2) - Classic PMD (most common phenotype) is “typically due to duplications of PLP1” (johari2023arehabilitationjourney pages 1-2) - SPG2 is often due to PLP1 deletions with milder phenotype (johari2023arehabilitationjourney pages 1-2)

4.4 Modifier genes / epigenetics

No modifier genes or epigenetic mechanisms were identified in the retrieved evidence for this run (beyond clinical mention of skewed X-inactivation affecting female carriers). (dharni2024ararecase pages 1-2)

5. Environmental information

PMD is a monogenic disorder; the retrieved evidence does not support specific environmental causes, lifestyle risk factors, or infectious triggers.

6. Mechanism / pathophysiology

6.1 Mechanistic chain (from variant to clinical manifestation)

Upstream: PLP1 dosage changes or missense variants alter PLP1 abundance/processing in oligodendrocytes (myelin-forming glia). (johari2023arehabilitationjourney pages 1-2, fukushima2024crisprcasrxmediatedknockdownof pages 1-2)

Cellular stress and downstream effects: A 2024 experimental report states that a major contributor is defective oligodendroglial myelin sheath formation triggered by “endoplasmic reticulum (ER) stress and subsequent unfolded protein response (UPR).” (fukushima2024crisprcasrxmediatedknockdownof pages 1-2)

Tissue-level outcome: CNS hypomyelination/dysmyelination produces diffuse white matter abnormalities on MRI and progressive motor and neurologic impairment. (manzke2025clinicalcharacteristicsof pages 1-2, dharni2024ararecase pages 1-2)

6.2 Recent mechanistic development (2024)

A 2024 letter describes rescue of PLP1-mutant cellular phenotypes: “incomplete cell shapes induced by PLP1 p.Ala243Val can be restored by knockdown of Rab7B using… CRISPR and CasRx (Cas13d),” and Rab7B knockdown promoted trafficking of mutant PLP1 to “LAMP1-positive organelles,” suggesting vesicle trafficking/lysosomal routing as a therapeutic lever. (Published 2024; DOI https://doi.org/10.1177/26331055241276873) (fukushima2024crisprcasrxmediatedknockdownof pages 1-2)

6.3 Suggested ontology terms

GO biological processes (suggested): myelination; response to endoplasmic reticulum stress; unfolded protein response; protein/vesicle trafficking; lysosome organization/targeting. (fukushima2024crisprcasrxmediatedknockdownof pages 1-2)

Cell types (Cell Ontology; suggested): oligodendrocyte. (fukushima2024crisprcasrxmediatedknockdownof pages 1-2)

7. Anatomical structures affected

7.1 Organ/system level

Primary system: central nervous system white matter (leukodystrophy/hypomyelination). (rogac2023opticalgenomemapping pages 1-2, manzke2025clinicalcharacteristicsof pages 1-2)

7.2 Imaging-supported affected structures

MRI/MRS findings in classic PMD include diffuse white matter signal abnormalities and atrophy of major white-matter and hindbrain structures (corpus callosum, cerebellum), with possible brainstem/internal capsule involvement. (manzke2025clinicalcharacteristicsof pages 1-2, manzke2025clinicalcharacteristicsof media 789d293e)

Suggested UBERON terms (examples): brain white matter; corpus callosum; cerebellum; brainstem; internal capsule.

8. Temporal development (natural history)

PMD typically has early onset (neonatal/infancy) and chronic progressive course, with severity depending on subtype (connatal vs classic vs SPG2 spectrum). (johari2023arehabilitationjourney pages 1-2, manzke2025clinicalcharacteristicsof pages 1-2)

9. Inheritance and population

9.1 Inheritance

X-linked inheritance is consistently reported. (wolf2025plp1relateddisorders pages 17-19, rogac2023opticalgenomemapping pages 1-2)

Genetic counseling summary (PLP1-related disorders): - If a mother carries the familial PLP1 variant, each pregnancy has 50% chance of transmission; males inheriting the variant are affected; females may be asymptomatic or have mild-to-moderate signs. (wolf2025plp1relateddisorders pages 17-19)

9.2 Epidemiology (statistics)

A 2023 report provides an international prevalence estimate of 1:90,000–1:750,000 births, varying by ethnic demographic context. (johari2023arehabilitationjourney pages 1-2)

10. Diagnostics

10.1 Clinical and MRI diagnosis

MRI is emphasized as central to diagnosis and phenotypic classification. (johari2023arehabilitationjourney pages 1-2)

A 2024 case report highlights a resource-limited workflow: - “Early diagnosis is crucial… with MRI serving as a potential alternative to genetic testing in resource-limited settings.” (Published online 2024-10-03; URL https://doi.org/10.18231/j.ijn.2024.037) (dharni2024ararecase pages 1-2) - MRI described “bilaterally symmetrical T2/FLAIR hyperintense and T1 hypointense signal alterations in the cerebral white matter and brainstem.” (dharni2024ararecase pages 1-2)

A 2025 imaging description (accepted 2024-10-30) reports hypomyelination with diffuse white matter hyperintensity and atrophy of the corpus callosum and cerebellum, with MRS changes (NAA/Cr decreased; mI/Cr increased). (manzke2025clinicalcharacteristicsof pages 1-2, manzke2025clinicalcharacteristicsof media 789d293e)

10.2 Genetic testing (real-world implementation)

A recommended testing strategy for PLP1-related disorders: 1) Deletion/duplication (CNV) testing (MLPA, targeted microarray, qPCR, FISH) (wolf2025plp1relateddisordersa pages 3-6) 2) If CNV negative, PLP1 sequence analysis for missense/nonsense/splice variants and small indels (wolf2025plp1relateddisordersa pages 3-6) 3) Alternative approaches: multigene leukodystrophy panel or exome/genome sequencing. (wolf2025plp1relateddisordersa pages 3-6)

Modern SV resolution: a 2023 Frontiers in Genetics report argues that optical genome mapping can resolve complex/inverted duplications not captured by standard CNV tests, improving prenatal and postnatal counseling. (Published 2023-07-25; URL https://doi.org/10.3389/fgene.2023.1173426) (rogac2023opticalgenomemapping pages 1-2)

10.3 Omics/biomarkers under development

The Ionis observational Rocket study explicitly targets biomarker characterization and progression measures. - Trial brief summary includes: “assess longitudinal changes in proteolipid protein 1 (PLP1) protein, disease-related biomarkers in CSF and blood, neuroimaging parameters… and… clinical… caregiver-reported outcome assessments.” (ClinicalTrials.gov, last update posted 2026-04-17; URL https://clinicaltrials.gov/study/NCT05659901) (NCT05659901 chunk 1)

10.4 Differential diagnosis

Imaging-based differentials mentioned include Salla disease and other leukodystrophies, ruled out by imaging in a 2024 case report. (dharni2024ararecase pages 1-2)

11. Outcome / prognosis

Prognosis is subtype-dependent: - Classic PMD: life expectancy “around young adulthood” and “commonly between adolescence to young adulthood.” (johari2023arehabilitationjourney pages 1-2) - Connatal PMD: death can occur in early childhood due to secondary complications. (johari2023arehabilitationjourney pages 1-2)

Longitudinal stability can occur in some individuals (e.g., a 32-year-old classic PMD case report describes stable MRI findings over a 5-year period despite longstanding disability). (johari2023arehabilitationjourney pages 1-2)

12. Treatment

12.1 Current standard of care (real-world implementation)

No definitive disease-modifying therapy is established; care is supportive and multidisciplinary, addressing spasticity, communication/swallowing, function, and seizures. - Supportive rehabilitation measures (play/occupational therapy, speech therapy, physiotherapy for spasticity/contractures, behavioral therapy) are described in a 2024 case report. (dharni2024ararecase pages 1-2) - Symptomatic medications reported in a longitudinal case include baclofen and botulinum toxin A for spasticity (case report context). (johari2023arehabilitationjourney pages 1-2)

12.2 Advanced/experimental therapeutics and clinical trials (focus on 2023–2024+ developments)

Antisense oligonucleotide (ASO) therapy targeting PLP1 duplication - Orbit (ION356): Phase 1b open-label multiple-ascending dose study, intrathecal ION356, enrolling ~24 pediatric male participants (2–17 years) with genetically confirmed PLP1 duplication; start date 2024-04-10 (actual); ClinicalTrials.gov first posted 2023-11-29; URL: https://clinicaltrials.gov/study/NCT06150716. (NCT06150716 chunk 1)

Biomarker and progression study supporting therapy development - Rocket: Observational integrated prospective/retrospective study (up to 32 participants) requiring PLP1 duplication; start 2022-10-03; primary completion estimated 2029-03; measures include CSF/blood PLP1 and biomarkers, MRI/MRS, and clinical/caregiver outcomes; URL: https://clinicaltrials.gov/study/NCT05659901. (NCT05659901 chunk 1)

Cell therapy/stem cell transplantation (historical but real-world implemented trial) - HuCNS-SC intracerebral transplantation (connatal PMD): Phase 1 safety/preliminary efficacy, enrollment 4, completed; includes MRI myelination assessment; URL: https://clinicaltrials.gov/study/NCT01005004. (NCT01005004 chunk 1) - Long-term follow-up study: enrollment 4, completed; URL: https://clinicaltrials.gov/study/NCT01391637. (NCT01391637 chunk 1)

12.3 Suggested MAXO terms (examples)

Physical therapy; occupational therapy; speech therapy; antispasticity treatment; seizure management; intrathecal antisense oligonucleotide therapy; stem cell transplantation; genetic counseling; prenatal testing; preimplantation genetic testing (PGT).

13. Prevention

There is no primary prevention for a monogenic disorder like PMD; prevention focuses on genetic counseling and reproductive options. - A clinical genetics resource states “prenatal and preimplantation genetic testing (PGT) are possible” when the familial PLP1 variant is known, while emphasizing limitations of phenotype prediction due to intrafamilial variability. (wolf2025plp1relateddisorders pages 17-19)

14. Other species / natural disease

No naturally occurring non-human PMD evidence was present in the retrieved context for this run.

15. Model organisms / experimental models

15.1 Cellular models and functional genomics (recent)

A 2024 study in an oligodendroglial differentiation model links PLP1 mutation to ER stress/UPR and demonstrates a functional-genomics style rescue via CRISPR/CasRx knockdown of Rab7B. (Published 2024; URL https://doi.org/10.1177/26331055241276873) (fukushima2024crisprcasrxmediatedknockdownof pages 1-2)

15.2 Human imaging phenotypes (for translational modeling)

A 2025 imaging figure provides a practical radiologic phenotype definition for modeling endpoints (white matter hyperintensity, corpus callosum/cerebellar atrophy, and MRS NAA/Cr↓ with mI/Cr↑), which can inform outcome measures in translational studies. (manzke2025clinicalcharacteristicsof media 789d293e)

Key visual evidence (diagnostic imaging phenotype)

The following figure captures representative MRI and MR spectroscopy abnormalities reported in a patient with classic PMD.

(manzke2025clinicalcharacteristicsof media 789d293e)

Summary table (for knowledge base ingestion)

Section	Key facts	Ontology/standard terms	Key sources
Identifiers	PMD is a severe/progressive X-linked recessive hypomyelinating leukodystrophy caused by PLP1 variants; OMIM disease ID 312080 and PLP1 OMIM gene ID 300401 are explicitly reported. ClinicalTrials.gov maps the condition to MeSH term Pelizaeus-Merzbacher Disease (D020371). Open Targets lists MONDO_0010714 Pelizeaus-Merzbacher spectrum disorder and subtype MONDO terms for connatal, transitional, classic, and female-carrier disease. Disease information here is derived from aggregated disease-level resources plus individual case reports/trials. (rogac2023opticalgenomemapping pages 1-2, NCT05659901 chunk 1)	MONDO: MONDO_0010714; MONDO_0017221 connatal form; MONDO_0017222 classic form; MONDO_0017223 transitional form; MONDO_0017224 female carriers. MeSH: D020371. Suggested disease label: hypomyelinating leukodystrophy type 1 / PLP1-related disorder.	Rogac et al., Front Genet, 2023-07-25, DOI: https://doi.org/10.3389/fgene.2023.1173426 (rogac2023opticalgenomemapping pages 1-2); ClinicalTrials.gov NCT05659901, first posted 2022-12-21, https://clinicaltrials.gov/study/NCT05659901 (NCT05659901 chunk 1)
Etiology/Genetics	Causal gene: PLP1. Variant classes include duplications, deletions, and point mutations. Quantitative breakdowns reported: Xq22 microduplications/PLP1 duplications ~60–70% of cases, point mutations 10–25%, deletions 5–10%; another source states PLP1 duplications account for 50–75% of clinically manifest variants. Gene-targeted deletion/duplication analysis detects ~60–70% of pathogenic variants; sequence analysis detects ~30–40%; whole-gene deletions occur in <2% of PMD phenotypes. Tandem duplications at Xq22 predominate; triplication/partial triplication/quintuplication and complex/inverted duplications are reported. Inheritance is X-linked; carrier mothers have a 50% transmission risk per pregnancy; affected males usually more severely affected, while females may be asymptomatic or mildly/moderately affected due to skewed X-inactivation/other factors. (akkus2023dörtailedenpelizaeusmerzbacher pages 1-2, rogac2023opticalgenomemapping pages 1-2, wolf2025plp1relateddisordersa pages 3-6, wolf2025plp1relateddisorders pages 17-19, dharni2024ararecase pages 1-2)	Gene: PLP1. Suggested HGNC symbol: PLP1. HPO inheritance term suggestion: X-linked recessive inheritance.	Akkuş & Özyavuz Çubuk, Turk J Pediatr Dis, 2023-07-11/2023-08-02, DOI: https://doi.org/10.12956/tchd.1275274 (akkus2023dörtailedenpelizaeusmerzbacher pages 1-2); Rogac et al., 2023-07-25, DOI above (rogac2023opticalgenomemapping pages 1-2); Wolf & van Spaendonk, PLP1-related disorders, 2025 text excerpt (wolf2025plp1relateddisordersa pages 3-6, wolf2025plp1relateddisorders pages 17-19)
Phenotypes/Natural history	Core features across sources: developmental delay, infantile hypotonia, nystagmus, spasticity/spastic quadriplegia or paraparesis, ataxia, dysarthria, dysphagia, optic atrophy/visual decline, tremor, behavioral/cognitive impairment; severe forms may include dystonia, seizures, laryngeal stridor, inability to walk or speak. Classic PMD often presents in the first year of life; connatal PMD presents in neonatal life with severe hypotonia and extrapyramidal signs; SPG2 is the mildest end, often first decade onset with spastic paraparesis/ataxia/autonomic dysfunction. Nystagmus may lessen over time while motor and cognitive impairment worsen. Forms 0–4 severity grading and connatal/transitional/classic/SPG2 spectrum are described. Female cases can occur. (johari2023arehabilitationjourney pages 1-2, manzke2025clinicalcharacteristicsof pages 1-2, dharni2024ararecase pages 1-2, rogac2023opticalgenomemapping pages 1-2)	Suggested HPO: developmental delay, infantile axial hypotonia, nystagmus, spasticity, spastic paraplegia, spastic quadriplegia, ataxia, dysarthria, dysphagia, optic atrophy, tremor, seizures, dystonia, developmental regression, stridor.	Johari et al., J Med Clin Res Rev, 2023-10-14, DOI: https://doi.org/10.33425/2639-944x.1349 (johari2023arehabilitationjourney pages 1-2); Manzke et al., Hum Genome Var, accepted 2024-10-30/published 2025-01, DOI: https://doi.org/10.1038/s41439-024-00306-8 (manzke2025clinicalcharacteristicsof pages 1-2); Dharni et al., IP Indian J Neurosci, 2024-10-03, DOI: https://doi.org/10.18231/j.ijn.2024.037 (dharni2024ararecase pages 1-2)
Diagnostics	Recommended molecular workflow: if PLP1-related disease is suspected, start with targeted deletion/duplication analysis (MLPA, targeted microarray, qPCR, FISH); if negative, proceed to PLP1 sequence analysis for missense/nonsense/splice/small indels; multigene panel or exome/genome testing are alternatives. Real-world methods used include MLPA plus chromosomal microarray; optical genome mapping can resolve complex/inverted duplications not characterized by routine CNV assays. MRI is central: severe forms show diffuse/confluent hypomyelination; milder/SPG2 can show tigroid/patchy hypomyelination. Reported MRI/MRS findings include diffuse T2/FLAIR white-matter hyperintensity, T1 hypointensity, involvement of internal capsules/brainstem, and atrophy of corpus callosum/cerebellum with decreased NAA/Cr and increased mI/Cr ratios. WGS has been evaluated as a first-line leukodystrophy tool in LeukoSEQ. (wolf2025plp1relateddisordersa pages 3-6, rogac2023opticalgenomemapping pages 1-2, akkus2023dörtailedenpelizaeusmerzbacher pages 1-2, manzke2025clinicalcharacteristicsof pages 1-2, manzke2025clinicalcharacteristicsof media 789d293e, NCT02699190 chunk 1, dharni2024ararecase pages 1-2)	Suggested terms: MRI white matter abnormality; hypomyelination; corpus callosum atrophy; cerebellar atrophy. MeSH trial mapping: D020371.	Wolf & van Spaendonk, 2025 text excerpt (wolf2025plp1relateddisordersa pages 3-6); Rogac et al., 2023-07-25 DOI above (rogac2023opticalgenomemapping pages 1-2); Manzke et al., 2025 DOI above + Figure 1 imaging summary (manzke2025clinicalcharacteristicsof pages 1-2, manzke2025clinicalcharacteristicsof media 789d293e); LeukoSEQ NCT02699190, results first posted 2025-06-15, https://clinicaltrials.gov/study/NCT02699190 (NCT02699190 chunk 1)
Prognosis/Epidemiology	Reported prevalence range: 1:90,000 to 1:750,000 births, varying by population. Prognosis depends on subtype: classic PMD is the most common phenotype and has life expectancy around young adulthood/adolescence to young adulthood; connatal PMD is most severe and death may occur in early childhood, though attentive care can prolong survival. PMD is usually chronic and progressive, though some individuals may show relative imaging stability over years despite clinical disability. (johari2023arehabilitationjourney pages 1-2, manzke2025clinicalcharacteristicsof pages 1-2)	Suggested HPO prognosis-related concepts: progressive neurologic deterioration; reduced life expectancy.	Johari et al., 2023-10-14, DOI above (johari2023arehabilitationjourney pages 1-2); Manzke et al., 2025 DOI above (manzke2025clinicalcharacteristicsof pages 1-2)
Treatments & trials	No definitive disease-modifying standard therapy is established; management is multidisciplinary and supportive: physiotherapy, occupational/play therapy, speech therapy, spasticity treatment (e.g., baclofen, botulinum toxin in case report), behavioral therapy, seizure counseling/antiepileptics as needed. Rocket observational biomarker study (NCT05659901) is recruiting; start 2022-10-03, estimated completion 2029-03, enrollment 32, focusing on CSF/blood PLP1 biomarkers, MRI/MRS, motor/spasticity/dysphagia/cognition/behavior/sleep outcomes; includes genetically confirmed PLP1 duplication, males 6 months–17 years. Orbit interventional ASO study of intrathecal ION356 (NCT06150716) is recruiting; first posted 2023-11-29, actual start 2024-04-10, estimated completion 2028-06, enrollment 24, phase 1b, in males 2–17 years with PLP1 duplication. Historical stem-cell trials: HuCNS-SC intracerebral transplantation in connatal PMD (NCT01005004) phase 1, enrollment 4, completed; long-term follow-up NCT01391637, enrollment 4, completed. Wolf excerpt also notes antisense oligonucleotide therapy and deferiprone in trials, while curcumin was not effective in a small human group. (johari2023arehabilitationjourney pages 1-2, dharni2024ararecase pages 1-2, NCT05659901 chunk 1, NCT06150716 chunk 1, NCT01391637 chunk 1, NCT01005004 chunk 1, wolf2025plp1relateddisorders pages 17-19)	Suggested MAXO: physical therapy, occupational therapy, speech therapy, seizure management, antispasticity treatment, stem cell transplantation, intrathecal antisense oligonucleotide therapy, genetic counseling, prenatal testing/PGT.	ClinicalTrials.gov NCT05659901 https://clinicaltrials.gov/study/NCT05659901 (NCT05659901 chunk 1); NCT06150716 https://clinicaltrials.gov/study/NCT06150716 (NCT06150716 chunk 1); NCT01005004 https://clinicaltrials.gov/study/NCT01005004 (NCT01005004 chunk 1); NCT01391637 https://clinicaltrials.gov/study/NCT01391637 (NCT01391637 chunk 1); Johari et al., 2023 DOI above (johari2023arehabilitationjourney pages 1-2); Dharni et al., 2024 DOI above (dharni2024ararecase pages 1-2)
Models/Mechanisms	Mechanistically, PMD/HLD1 reflects defective CNS myelin formation from PLP1 dosage imbalance or mutation. One 2024 experimental paper states a “major cause” is incomplete/defective oligodendroglial myelin sheath formation triggered by ER stress and unfolded protein response (UPR); PLP1 p.Ala243Val impairs oligodendroglial morphological differentiation, and Rab7B knockdown via CRISPR/CasRx partially restored morphology and promoted trafficking to LAMP1-positive organelles in an oligodendroglial cell line. Another 2024 resource reports generation of a PLP1-C33Y human iPSC line by CRISPR/Cas9 for disease modeling. Clinical review/case sources additionally describe PLP overexpression causing nonfunctional myelin protein and oligodendrocyte dysfunction. (fukushima2024crisprcasrxmediatedknockdownof pages 1-2, johari2023arehabilitationjourney pages 1-2)	Suggested GO: myelination; response to endoplasmic reticulum stress; unfolded protein response; protein trafficking; lysosome. Suggested CL: oligodendrocyte. Suggested UBERON: central nervous system white matter, corpus callosum, cerebellum, brainstem.	Fukushima et al., Neuroscience Insights, 2024, DOI: https://doi.org/10.1177/26331055241276873 (fukushima2024crisprcasrxmediatedknockdownof pages 1-2); Schreiber & Zafeiriou, Stem Cell Research, 2024-02, DOI: https://doi.org/10.1016/j.scr.2023.103276 (supporting model generation noted in retrieved paper list, not otherwise detailed in context); Johari et al., 2023 DOI above (johari2023arehabilitationjourney pages 1-2)

Table: This table condenses key disease knowledge for Pelizaeus–Merzbacher disease, including identifiers, genetics, phenotype, diagnostics, prognosis, treatment trials, and mechanisms. It emphasizes quantitative variant distributions and active clinical studies using only facts supported by the cited context IDs.

Expert synthesis / analysis (evidence-based)

PLP1 CNV is the dominant genetic mechanism in clinically manifest PMD, with duplication frequencies consistently reported in the majority range (50–75% or ~60–70%), supporting CNV-first genetic testing (MLPA/microarray/qPCR/FISH) as a pragmatic diagnostic front line before sequencing. (rogac2023opticalgenomemapping pages 1-2, akkus2023dörtailedenpelizaeusmerzbacher pages 1-2, wolf2025plp1relateddisordersa pages 3-6)
Therapeutic development is shifting toward molecularly stratified cohorts, particularly PLP1 duplication classic PMD, as evidenced by Ionis’ biomarker study (Rocket) and ASO therapeutic trial (Orbit/ION356) requiring genetic confirmation of PLP1 duplication and using CSF/blood PLP1 plus MRI/MRS and functional outcomes. (NCT05659901 chunk 1, NCT06150716 chunk 1)
Mechanistic convergence on oligodendrocyte stress pathways (ER stress/UPR) and proteostasis/trafficking suggests druggable nodes beyond PLP1 itself; the Rab7B knockdown study provides a concrete example of targeting vesicular trafficking/lysosomal routing to ameliorate a PLP1-mutation phenotype in vitro. (fukushima2024crisprcasrxmediatedknockdownof pages 1-2)

Notes on limitations of this run

ICD-10/ICD-11 codes and Orphanet identifiers were not present in the retrieved full-text context; these should be added from ICD/Orphanet sources during curation.
Several high-priority 2023–2024 review articles and interventional clinical publications were not accessible in full text via the current retrieval; the report therefore emphasizes trials registry records and available peer-reviewed articles/case studies.

References

(rogac2023opticalgenomemapping pages 1-2): Mihael Rogac, Anja Kovanda, Luca Lovrečić, and Borut Peterlin. Optical genome mapping in an atypical pelizaeus-merzbacher prenatal challenge. Frontiers in Genetics, Jul 2023. URL: https://doi.org/10.3389/fgene.2023.1173426, doi:10.3389/fgene.2023.1173426. This article has 7 citations and is from a peer-reviewed journal.
(fukushima2024crisprcasrxmediatedknockdownof pages 1-2): Nana Fukushima, Yuki Miyamoto, and Junji Yamauchi. Crispr/casrx-mediated knockdown of rab7b restores incomplete cell shape induced by pelizaeus-merzbacher disease-associated plp1 p.ala243val. Neuroscience Insights, Jan 2024. URL: https://doi.org/10.1177/26331055241276873, doi:10.1177/26331055241276873. This article has 4 citations.
(NCT05659901 chunk 1): Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Pelizaeus-Merzbacher Disease. Ionis Pharmaceuticals, Inc.. 2022. ClinicalTrials.gov Identifier: NCT05659901
(wolf2025plp1relateddisordersa pages 3-6): NI Wolf and RML van Spaendonk. Plp1-related disorders. Unknown journal, 2025.
(johari2023arehabilitationjourney pages 1-2): Azri Johari, Ling Lan, and Harsh Kandpal. A rehabilitation journey with pelizaeus-merzbacher disease (pmd). Journal of Medical - Clinical Research & Reviews, Oct 2023. URL: https://doi.org/10.33425/2639-944x.1349, doi:10.33425/2639-944x.1349. This article has 1 citations.
(akkus2023dörtailedenpelizaeusmerzbacher pages 1-2): Nejmiye AKKUŞ and Pelin ÖZYAVUZ ÇUBUK. Dört aileden pelizaeus-merzbacher sendromlu altı hastanın klinik ve moleküler sitogenetik analizleri. Turkish Journal of Pediatric Disease, pages 1-6, Jul 2023. URL: https://doi.org/10.12956/tchd.1275274, doi:10.12956/tchd.1275274. This article has 0 citations.
(wolf2025plp1relateddisorders pages 17-19): NI Wolf and RML van Spaendonk. Plp1-related disorders. Unknown journal, 2025.
(dharni2024ararecase pages 1-2): Tania Dharni, Sandeep Aggarwal, Manmeet Kaur Sodhi, Vaibhav Oberoi, Pinki Meena, Asgar Ali, Nilesh Patidar, and Ratul Khanna. A rare case of radiologically diagnosed pelizaeus-merzbacherś disease (pmd) in a female infant. IP Indian Journal of Neurosciences, 10:171-173, Oct 2024. URL: https://doi.org/10.18231/j.ijn.2024.037, doi:10.18231/j.ijn.2024.037. This article has 0 citations.
(manzke2025clinicalcharacteristicsof pages 1-2): Pedro Manzke, Pedro Renato P. Brandão, Talita Balieiro, Diógenes Diego de Carvalho Bispo, Maria Joana Osório, and Gustavo Barcelos Barra. Clinical characteristics of the ala21val variant in the myelin proteolipid protein 1 (plp1) gene associated with pelizaeus-merzbacher disease in a brazilian male patient. Human Genome Variation, Jan 2025. URL: https://doi.org/10.1038/s41439-024-00306-8, doi:10.1038/s41439-024-00306-8. This article has 0 citations.
(manzke2025clinicalcharacteristicsof media 789d293e): Pedro Manzke, Pedro Renato P. Brandão, Talita Balieiro, Diógenes Diego de Carvalho Bispo, Maria Joana Osório, and Gustavo Barcelos Barra. Clinical characteristics of the ala21val variant in the myelin proteolipid protein 1 (plp1) gene associated with pelizaeus-merzbacher disease in a brazilian male patient. Human Genome Variation, Jan 2025. URL: https://doi.org/10.1038/s41439-024-00306-8, doi:10.1038/s41439-024-00306-8. This article has 0 citations.
(NCT06150716 chunk 1): Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered ION356 in Participants With Pelizaeus Merzbacher Disease (PMD). Ionis Pharmaceuticals, Inc.. 2024. ClinicalTrials.gov Identifier: NCT06150716
(NCT01005004 chunk 1): Study of Human Central Nervous System (CNS) Stem Cells Transplantation in Pelizaeus-Merzbacher Disease (PMD) Subjects. StemCells, Inc.. 2009. ClinicalTrials.gov Identifier: NCT01005004
(NCT01391637 chunk 1): Long-Term Follow-Up Study of Human Stem Cells Transplanted in Subjects With Connatal Pelizaeus-Merzbacher Disease (PMD). StemCells, Inc.. 2011. ClinicalTrials.gov Identifier: NCT01391637
(NCT02699190 chunk 1): Adeline Vanderver, MD. LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies. Children's Hospital of Philadelphia. 2017. ClinicalTrials.gov Identifier: NCT02699190

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Clinical Trials

Source YAML

References & Deep Research

References

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Comprehensive Disease Characteristics Research Report: Pelizaeus–Merzbacher Disease (PMD)

Target disease

1. Disease information

1.1 Overview (current understanding)

1.2 Key identifiers (as available in the retrieved sources)

1.3 Synonyms / alternative names

1.4 Evidence source type

2. Etiology

2.1 Primary causal factors

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes

3.1 Core phenotype spectrum (symptoms/signs)

3.2 Subtypes and severity (current clinical framing)

3.3 Age of onset, progression, and course

3.4 Quality-of-life impact

3.5 Suggested HPO terms (non-exhaustive; for knowledge base mapping)

4. Genetic / molecular information

4.1 Causal genes

4.2 Pathogenic variant types and functional consequences

4.3 Genotype–phenotype correlations (clinically used heuristics)

4.4 Modifier genes / epigenetics

5. Environmental information

6. Mechanism / pathophysiology

6.1 Mechanistic chain (from variant to clinical manifestation)

6.2 Recent mechanistic development (2024)

6.3 Suggested ontology terms

7. Anatomical structures affected

7.1 Organ/system level

7.2 Imaging-supported affected structures

8. Temporal development (natural history)

9. Inheritance and population

9.1 Inheritance

9.2 Epidemiology (statistics)

10. Diagnostics

10.1 Clinical and MRI diagnosis

10.2 Genetic testing (real-world implementation)

10.3 Omics/biomarkers under development

10.4 Differential diagnosis

11. Outcome / prognosis

12. Treatment

12.1 Current standard of care (real-world implementation)

12.2 Advanced/experimental therapeutics and clinical trials (focus on 2023–2024+ developments)

12.3 Suggested MAXO terms (examples)